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Abstract  
 
Introduction: Traditionally, research in the clinical-high risk (CHR) for psychosis 
population has focused on a dichotomous measure of transition to psychosis. In light of 
declining transition rates, it is becoming increasingly important to focus on continuous 
measures of outcome such as functional status. Moreover, studies have almost exclusively 
utilised clinically presenting/help-seeking samples, limiting the generalisability of findings. 
Utilising a sample of CHR participants primarily recruited from the general population, 
this study aimed to investigate the relationship between cognitive performance, clinical 
symptoms and functioning at baseline; and baseline predictors of functional outcome at 6- 
and 12-months follow-up. 
 
Methods: Data was available for 129 CHR individuals at baseline, 86 CHR individuals at 
6-month follow-up and 69 CHR individuals at 12-month follow-up. 46 CHR-negative 
(CHR-N) participants (n = 40 at follow-up) who did not meet CHR criteria and 55 healthy 
controls (HCs) were also included. All participants were assessed on clinical, functional 
and cognitive variables at baseline. Functional outcome was assessed using the global 
assessment of functioning (GAF) score at follow-up.  
 
Results: Emotion recognition response time (RT), either alone or in combination with 
other cognitive variables, was associated with clinical symptoms and functioning at 
baseline. Over half of CHR individuals were classified as having a poor functional 
outcome (PFO) at 6- and 12-months with functioning remaining relatively stable over time. 
PFO at 6-month follow-up was predicted by impairments in attention and processing 
speed, working memory, global functioning and role functioning at baseline. PFO at 12-
month follow-up was predicted by reduced attention accuracy and poor global functioning 
at baseline. The areas under the curve for the 6- and 12-month prediction models were 
0.911 and 0.818, respectively, demonstrating high discriminative abilities. 
 
Discussion: These findings emphasise the importance of focusing on a broader outcome of 
interest in individuals at CHR for psychosis, rather than the arbitrary threshold of 
psychosis transition. At baseline, neurocognitive and social cognitive performance were 
predictive of clinical symptoms and functioning whilst reduced neurocognitive 
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performance and functional impairments at baseline predicted PFO at follow-up. These 
findings highlight the importance of such predictive factors for detecting false positives as 
well as the potential benefits of interventions incorporating vocational and educational 
rehabilitation and cognitive remediation. Furthermore, given that the majority of the CHR 
sample were recruited from the general population, clinical early detection teams should 
extend their services into the community in order to improve access to such interventions.  
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1.0 Introduction 
 
1.1 Schizophrenia - definition and epidemiology. 
 
Schizophrenia, the most severe manifestation of psychosis, is a debilitating mental illness 
characterised by a loss of contact with reality and disturbances in thinking, speech, 
perception, emotion and behaviour. Worldwide, it has been ranked as the severest disorder, 
in terms of disability, out of 220 mental and physical health disorders (Salomon et al., 
2012). Indeed, individuals with schizophrenia tend to die 20 years earlier, on average, than 
the general population partly due to an increased rate of suicide - an approximate lifetime 
risk of 5% (Hor & Taylor, 2010) and under-diagnosis of physical health conditions 
(Laursen, Nordentoft, & Mortensen, 2014). Overall, the total societal cost of 
schizophrenia in England is estimated at £11.8 billion per year (Andrew, Knapp, McCrone, 
Parsonage, & Trachtenberg, 2012). 
 
With a lifetime prevalence of approximately 1% (Sisti & Calkins, 2016), schizophrenia 
typically strikes between the ages of 16 and 35 with males displaying an earlier onset than 
females by about 5 years (Linden, 2011). As well as reporting a median incidence rate of 
15.2 per 100,000 persons per year, systematic reviews of studies published between 1965 
and 2002 (McGrath et al., 2004b; McGrath, Saha, Chant, & Welham, 2008) concluded that 
individuals were more likely to develop schizophrenia if they were male versus female (in 
the order of 1.4:1); lived in urban sites rather than mixed urban/rural sites; and were 
migrants as opposed to native-born individuals. 
 
1.2 The history of schizophrenia. 
 
Although the term “schizophrenia” was coined relatively recently, descriptions of 
associated symptoms have been documented since antiquity; grouped under various 
disorders including phrenesis, melancholia and mania (Jablensky, 2010). Case descriptions 
dating back to the mid-19th century show that European psychiatrists had begun elucidating 
disorders of unknown cause, typically affecting the young and often resulting in a dramatic 
deterioration of intellect with little hope of recovery or remission. In France, Morel (1860) 
used the term “dementia praecox” to refer to such disorders whereas, in Scotland, Clouston 
(1904) proposed the idea of an “adolescent insanity”. In Germany, Kahlbaum (1874) and 
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his protégé Hecker (1871) added the diagnostic categories “catatonia” and “hebephrenia”, 
respectively. Whereas catatonia described patients immobilised by psychological factors, 
hebephrenia referred to patients with erratic, bizarre and regressed behaviours. 
 
Noting the commonalities between catatonia and hebephrenia, German physician Emil 
Kraepelin (1899, 1919) added the term “paranoia” to describe highly suspicious patients 
and grouped these three mental disorders under the heading coined by Morel 40 years 
before - dementia praecox. He distinguished dementia praecox from “manic-depressive 
insanity” (now bipolar disorder) which was characterised by an episodic course, absence of 
mental deterioration and a more positive outcome – a distinction referred to as “The 
Kraepelin Dichotomy” (Lake, 2012).   
 
However, Swiss psychiatrist Eugen Bleuler (1911) disagreed with Kraepelin’s dementia 
praecox. On observation of his patients, he noticed that the disorder was not confined to 
adolescence and early adulthood and did not inevitably result in cognitive deterioration – 
in fact, remission could be achieved. He is credited with introducing the term 
schizophrenia, derived from the Greek words “schizo” (split) and “phren” (mind), to 
describe the fragmentation of mental functions (Schlosser, Garrett, & Vinogradov, 2014). 
While Kraepelin viewed schizophrenia as a single disease, Bleuler believed it comprised a 
group of closely related illnesses (Baldwin, 2016). He broadened Kraepelin’s narrow 
definition by dividing the symptoms of schizophrenia into two distinct categories: 
fundamental and accessory (Buller & Sapin, 2016; Nickl-Jockschat & Abel, 2016). The 
fundamental symptoms, referred to as Bleuler’s 4 As, were purported to be pathognomonic 
in that they were unique to schizophrenia, occurring in all patients. These are loosening of 
association, affective incongruence, ambivalence and autism – now regarded as negative 
symptoms. On the other hand, accessory symptoms such as hallucinations and delusions – 
now classified as positive symptoms - could occur in a variety of different disorders and 
therefore, were not essential for a schizophrenia diagnosis. 
 
This emphasis on negative rather than positive symptoms later reversed. Jaspers (1946) 
believed that the core defect in schizophrenia was impairment of empathic communication 
and that “un-understandability” of individual experience was pathognomonic. Influenced 
by Jaspers, Kurt Schneider (1959) defined 11 first-rank symptoms which he considered to 
be diagnostic of schizophrenia. These comprise audible thoughts; voices arguing; voices 
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commenting on one’s action; influence playing on the body, somatic passivity; thought 
withdrawal; thoughts ascribed to others (thought insertion); diffusion or broadcasting of 
thoughts; “made” feelings; “made” impulses (drives); and “made” volitional acts (Mellor, 
1970). In contrast to the Bleulerian approach, Schneider’s first-rank symptoms are closely 
related to positive symptoms.  
 
Kraepelinian chronicity, Bleulerian negative symptoms and Schneiderian positive 
symptoms have been incorporated into the diagnostic criteria of the Diagnostic and 
Statistical Manual of Mental Disorders (DSM; from DSM-I to DSM-IV) and the 
International Statistical Classification of Diseases (ICD; from ICD-6 to ICD-10), although 
the specific emphasis placed on these three aspects has changed over time (Altamura, 
Fagiolini, Galderisi, Rocca, & Rossi, 2014). In the ICD-10 (World Health Organisation 
[WHO], 1992), DSM-III (American Psychiatric Association [APA], 1980) and DSM-IV 
(APA, 1994), the presence of one first-rank symptom was deemed symptomatically 
sufficient for a schizophrenia diagnosis (Nordgaard, Arnfred, Handest, & Parnas, 2008). 
Since then, doubts have been raised regarding the predictive utility of first-rank symptoms. 
Specifically, Soares-Weiser et al. (2015) reviewed 20 studies and reported that first-rank 
symptoms differentiated schizophrenia from all other diagnoses with a sensitivity of 57% 
and a specificity of 81.4%. Therefore, in the current DSM-5 (APA, 2013) and available 
draft of the ICD-11 (Luciano, 2015), at least two first-rank symptoms and at least one 
psychotic symptom is required for a schizophrenia diagnosis (Tandon et al., 2013).  
 
1.3 Positive and negative symptoms of schizophrenia. 
 
The idea of referring to schizophrenia symptoms as either positive or negative originated in 
the 1800s when neurologist Hughlings Jackson (1931) used the terms to describe deficits 
experienced by his patients. He believed that positive symptoms reflected an excess or 
distortion of normal function whereas negative symptoms represented a diminution or loss 
of normal function (Andreasen, 2010).  
 
The concept of positive and negative symptoms was operationalised in the type I/type II 
model of schizophrenia proposed by Crow (1980). Type I schizophrenia is characterised by 
positive symptoms (including hallucinations, delusions and thought disorders); arises from 
dopaminergic overactivity; responds well to antipsychotic medication; and has favourable 
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long-term prognosis. Conversely, Type II schizophrenia is characterised by negative 
symptoms (social withdrawal, lack of affect and reduced motivation); arises from structural 
brain abnormalities; responds poorly to antipsychotic medication; and has poor long-term 
outcome (Beck, Rector, Stolar, & Grant, 2009; Jablensky, 2010). Crow (1985) later 
amended the original model by replacing the diametric “types” with a positive and a 
negative dimension, acknowledging that both symptoms can co-occur in the same 
individual.  
 
More recently, the authors of the DSM-5, have considered the addition of a further 
classification category – cognitive symptoms – which includes difficultly in sustaining 
attention; low psychomotor speed; poor abstract thinking; and poor problem solving. 
However, this has been rejected due to a lack of evidence and so, cognitive symptoms 
remain part of the negative symptoms in the DSM-5 (Ebenezer, 2015). 
 
1.4 The course of schizophrenia. 
 
Schizophrenia develops through four sequential phases: the premorbid, prodromal, 
psychotic and stable phases (Ray, 2017; Tandon, Nasrallah, & Keshavan, 2009). Typically, 
negative symptoms are predominant in the nonpsychotic period whereas positive 
symptoms manifest during psychotic episodes (Kandel et al., 2000). The initial premorbid 
phase is characterised by subtle and nonspecific problems with cognition, motor and social 
functioning. Next is the prodromal phase, heralding the onset of attenuated (subthreshold) 
psychotic symptoms (APS) or basic symptoms (BS) with an associated decline in 
functioning. The length of this phase varies from a mean of 2 years (McGorry & Edwards, 
1997) up to 5 years (Häfner, 2003; Häfner et al., 1992). Psychotic symptoms become 
apparent in the following psychotic phase which marks the formal onset of schizophrenia. 
In this phase, patients experience repeated episodes of psychosis separated by intermittent 
blocks of remission. Decline in functioning is generally greatest during the first 5 years 
after the first psychotic episode. The final, stable phase is characterised by a reduction of 
psychotic symptoms and an increase in both negative symptoms and stable cognitive/social 
deficits. Notably, varying degrees of remission, sometimes amounting to permanent 
recovery, can be achieved at each stage (Torgalsbøen & Rund, 2002). 
 
1.5 Genetic and environmental risk factors. 
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The two-hit hypothesis of schizophrenia suggests that early developmental risk factors (i.e. 
genetic predisposition, environmental stressor) function as a “first hit”, rendering an 
individual susceptible to a “second hit” later in development (Fatemi & Folsom, 2009). 
This second hit (i.e. an environmental factor) is necessary to trigger the onset of the 
disorder.  
 
1.5.1 Genetics. 
 
1.5.1.1 Pre-molecular genetics. 
 
Twin, family and adoption studies have demonstrated that having a close biological 
relative with schizophrenia is the strongest risk factor for developing a psychotic disorder 
(Henriksen, Nordgaard, & Jansson, 2017). Monozygotic twins, who share 100% of their 
genes, have an increased propensity to develop schizophrenia compared to dizygotic twins, 
who share 50% of their genes. Recently, utilising data from the Danish Twin Register, 
Hilker et al. (2018) estimated the heritability of schizophrenia to be 79%. Pooling 
European twin studies from 1963-1987, Gottesman (1991) found a concordance rate of 
48% for monozygotic twins and 17% for dizygotic twins in line with later European and 
Japanese twin studies from 1992-1999 (Cardno & Gottesman 2000). Gottesman (1991) 
also conducted a meta-analysis of family studies, noting that risk for third-degree relatives 
(2%) was only slightly greater than the general population risk; second-degree relatives 
had a risk of around 5%; while first-degree relatives had a risk close to 10%. In order to 
separate genetic and rearing environment effects, adoption studies are critical. In one of the 
first large adoption studies, Heston (1966) identified 47 adopted children whose biological 
mother had a diagnosis of schizophrenia and found that 10.6% later developed the disorder 
themselves in contrast to 0% of 50 control adoptees. 
 
1.5.1.2 Molecular genetics. 
 
The genetic architecture of schizophrenia is highly polygenic, with specific contributions 
from common genetic variants of small effect and rare genetic variants of larger effect. Of 
note, many of the discovered associations are not specific to schizophrenia; in contrast, 
they indicate a genetic vulnerability to several psychiatric disorders including major 
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depressive disorder (MDD), attention deficit hyperactivity disorder (ADHD) and bipolar 
disorder (Anttila et al., 2018). 
 
Genome-wide association studies (GWASs) of single nucleotide polymorphisms (SNPs) 
have provided convincing evidence for common genetic variants with small odds ratios 
(ORs), generally < 1.2 (Rees, O’Donovan, & Owen, 2015). Given the modest effect size, 
GWASs screen hundreds of thousands to millions of common genetic variants in order to 
provide adequate statistical power. One seminal GWAS (Schizophrenia Working Group of 
the Psychiatric Genomics Consortium, 2014) of > 35,000 cases identified 108 independent 
loci associated with schizophrenia, 83 of which were novel findings. Overall, SNPs in the 
extended major histocompatibility complex (MHC) locus on chromosome 6 – an area 
known to play a central role in immune function - were most significantly associated with 
schizophrenia. Consistent with pathophysiological hypotheses, loci containing the 
dopamine D2 receptor (DRD2 – the ultimate schizophrenia candidate gene) and several 
glutamate receptors were also associated with the disorder.  
 
Collectively, common genetic variants are estimated to explain between a quarter and a 
half of the variance in genetic liability – leaving a large proportion unaccounted for 
(International Schizophrenia Consortium, 2009). Studies of copy number variation (CNV), 
single nucleotide variants (SNVs) and small insertion and deletions (indels) additionally 
link rare genetic variants, with large ORs of ~2-20, to the aetiology of schizophrenia (Rees 
et al., 2015). 
 
Rare, de novo or inherited CNVs are defined as deletions and duplications of the genomic 
sequence that typically range in length from 1 kilobase (kb) to several megabase (Mb) 
pairs (Kirov, 2015). Large (> 100 kb), rare (< 1% in the population) CNVs are increased 
1.15-fold in individuals with schizophrenia compared to controls (International 
Schizophrenia Consortium, 2008). Specifically, robust associations have been uncovered 
between schizophrenia and the following large, rare CNVs: deletions at 1q21.1, Neurexin 1 
(NRXN1), 3q29, 15q13.3 and 22q11.2 as well as duplications at 16p13.1 and 16p11.2 
(Henriksen et al., 2017). They affect multiple genes (apart from NRXN1) which are 
important for cell signalling, brain development and glutamate transmission. 
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Whole-exome sequencing studies have further implicated rare genetic variants in 
schizophrenia. This technique identifies DNA variants within the 1% protein-coding 
regions or genes (exons) of the genome (exome), permitting evaluation of gene mutations 
at single-base resolution. Purcell et al. (2014) explored rare SNVs and indels using exome 
sequencing and identified a polygenic burden, arising from rare (< 1 in 10,000) mutations 
distributed across many genes from a selection of 2,546 genes previously linked to 
schizophrenia by GWAS, CNV and de novo SNV studies. Specifically, the total count for 
mutations was 1527 in schizophrenia subjects versus 1383 in controls.  
 
However, the absence of 100% concordance between monozygotic twins and the failure of 
GWAS to identify major genetic candidates implies a potential aetiologic role of a variety 
of environmental factors in the development of schizophrenia.  
 
1.5.2 Prenatal/perinatal environmental risk factors. 
 
1.5.2.1 Obstetric complications. 
 
Obstetric complications, particularly those associated with hypoxia, contribute to 
schizophrenia susceptibility, albeit with a modest effect (ORs ~2; Geddes & Lawrie, 
1995). In a meta-analysis utilising population-based data, M. Cannon, Jones, and Murray 
(2002) distinguished three groups of complications significantly associated with 
schizophrenia: (1) pregnancy complications (bleeding, diabetes, preeclampsia and rhesus 
incompatibility); (2) abnormal fetal growth and development (low birth weight, congenital 
malformations and small head circumference); and (3) delivery complications (asphyxia, 
uterine atony and emergency caesarean section). A previous individual patient meta-
analysis (Geddes et al., 1999), involving 12 studies on 700 schizophrenia participants and 
835 controls, specifically identified premature rupture of membranes, gestational age < 37 
weeks and use of resuscitation or an incubator as significant risk factors for developing 
schizophrenia. Additional associations between schizophrenia and birth weight < 2500 
grams or use of forceps during delivery were of borderline significance. Such obstetric 
complications even confer risk to individuals in the prodromal phase of schizophrenia. 
According to Kotlicka-Antczak et al. (2017), a history of at least one obstetric 
complication is associated with an increased risk of transition to the full-blown disorder 
(OR of 6.57). 
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1.5.2.2 Infections. 
 
Prenatal infections such as influenza, rubella, Toxoplasma gondii and type 2 herpes virus 
are considered plausible risk factors for schizophrenia. P. R. Nielsen, Meyer, and 
Mortensen (2016) recently reported that any maternal hospitalisation for infection during 
pregnancy was associated with a 1.32-fold increased risk of schizophrenia in offspring. 
This effect remained significant after adjustment for parental history of psychiatric 
admission and degree of urbanicity although relative risk was attenuated to 1.16-fold. 
Studies using prenatal serum samples, however, have documented that prenatal exposure to 
rubella and first trimester exposure to influenza confers a 10-20-fold and 7-fold increase in 
risk of later schizophrenia, respectively (Brown, 2006). One prevalent hypothesis suggests 
that stimulation of the cytokine response could be responsible for mediating the 
relationship between infection and schizophrenia. Certainly, maternal levels of tumour 
necrosis factor-alpha (TNF-α) – a major proinflammatory cytokine - have been associated 
with psychotic disorders among offspring (Buka et al., 2001). 
 
1.5.2.3 Nutrition. 
 
The strongest evidence relating maternal malnutrition during pregnancy to schizophrenia in 
offspring derives from analysis of data obtained from two major famines. Those conceived 
to the most malnourished mothers during the Dutch Hunger Winter of 1944-45 (Lumey, 
Stein, & Susser, 2011) and the Chinese Famine from 1959-61 (St Clair et al., 2005) 
showed a twofold increased risk of schizophrenia. Several micronutrient deficiencies, 
including folate, essential fatty acids, retinoids, iron and vitamin D, have been 
hypothesised to mediate this association. In particular, levels of vitamin D appear to 
inversely correlate with negative and depression symptoms in those with psychosis 
(Nerhus et al., 2016) while vitamin D supplementation (≥ 2000 international units/day) 
during the first year of life has been shown to reduce the risk of developing schizophrenia 
in Finish male infants (McGrath et al., 2004a). 
 
1.5.2.4. Season of birth. 
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Schizophrenia often affects persons born during the late winter and early spring – a 
phenomenon known as the seasonality effect (Carlson, 2013). Possible explanations 
include maternal exposure to winter-borne viruses and low prenatal vitamin D. In a meta-
analysis of eight studies from the northern hemisphere, a pooled OR of 1.07 and a 
population attributable risk of 3.3% for winter/spring births was detected (Davies, 
Welham, Chant, Torrey, & McGrath, 2003). However, while the seasonality effect is 
robust in the northern hemisphere, a meta-analysis performed on data from 11 southern 
hemisphere studies (in Australia, South Africa and the Reunion Islands) did not support an 
effect (McGrath & Welham, 1999), corroborating findings from a plethora of studies.  
 
1.5.2.5 Place of birth. 
 
The relative risk of developing schizophrenia when born in an urban vs. rural environment 
is about 2.4 according to major population-based studies in the Netherlands (Marcelis, 
Navarro-Mateu, Murray, Selten, & Van Os, 1998) and Denmark (Mortensen et al., 1999). 
Since urban birth was relatively frequent in both studies, a substantial population 
attributable risk of approximately 30% was calculated for this variable. Factors attributable 
to urbanicity, such as air pollution, toxins, vitamin D deficiency and stress, are assumed to 
underlie this effect (Zwicker, Denovan-Wright, & Uher, 2018). However, most people who 
are born in urban areas are also brought up there, making it difficult to disentangle prenatal 
and perinatal effects from those operating later in childhood. In fact, Pedersen and 
Mortensen (2001) stated that a dose-response relationship, between years spent in an urban 
environment during upbringing and later emergence of schizophrenia, accounts for 15% of 
relevant cases. 
 
1.5.3 Later environmental risk factors. 
 
1.5.3.1 Substance abuse. 
 
Risk factors associated with psychosis later in development are largely substance use-
related. On investigation of Danish national registers, S. M. Nielsen, Toftdahl, Nordentoft, 
and Hjorthøj (2017) found that abuse of cannabis, alcohol, hallucinogens, sedatives and 
other substances significantly increased the risk of developing schizophrenia. Cannabis and 
alcohol presented as the strongest factors, increasing risk by 5 and 3 times, respectively. 
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Interestingly, the risk remained significant even 10–15 years following a diagnosis of 
substance abuse. The relationship between premorbid cannabis use and schizophrenia is 
evidenced by the positive dose-response relationship between cannabis use and psychosis 
(Marconi, Di Forti, Lewis, Murray, & Vassos, 2016) and the earlier onset of psychosis, by 
up to 2.7 years, in those with a history of cannabis use compared to those with no history 
(Donoghue et al., 2014). Of course, not all individuals using cannabis develop 
schizophrenia, leading to the proposition that cannabis use is only a risk factor in a 
subgroup of genetically vulnerable subjects, specifically through interference with the 
neurodevelopmental role of endocannabinoid (Mallet, Ramoz, Le Strat, Gorwood, & 
Dubertret, 2017). 
 
1.5.3.2 Childhood adversity. 
 
Childhood adversities, including neglect, abuse (emotional, psychological, physical and 
sexual), peer bullying, parental loss or divorce and poverty have been strongly implicated 
in the development of psychotic disorders (Morgan & Gayer-Anderson, 2016). A meta-
analysis of 36 studies reported that those with psychosis were 2.72 times more likely to 
have been exposed to childhood adversity than controls, with an estimated population 
attributable risk of 33% (Varese et al., 2012). Remarkably, Kelleher et al. (2013b) found 
that cessation of childhood trauma (physical assault and bullying) predicted subsequent 
cessation of psychotic experiences in a cohort of 1,112 adolescents.  
 
Regarding symptomatology, childhood adversities may influence the severity of delusions 
and hallucinations in a dose-response relationship (Muenzenmaier et al., 2015). Indeed, 
childhood sexual abuse has been linked to auditory hallucinations in females with first-
episode schizophrenia (FES; Misiak, Moustafa, Kiejna, & Frydecka, 2016). Various 
mechanisms have been proposed to mediate the relationship between childhood adversity 
and psychosis including hypothalamic-pituitary-adrenal (HPA) axis dysregulation, reduced 
levels of brain-derived neurotrophic factor (BDNF), increased levels of inflammatory 
markers and metabolic dysregulation (Misiak et al., 2017). 
 
1.5.3.3 Migration. 
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The risk of schizophrenia for first- and second-generation migrants is between 2 and 4.5 
times that of the majority ethnic group under investigation, although the exact risk varies 
by ethnicity and setting (Tortelli et al., 2015). For example, in the United Kingdom, 
African-Caribbean migrants are at greatest risk, with rates 9 times higher than White 
British people (Fearon et al., 2006) while in the Netherlands, more recent North African 
migrants are at greatest risk, with rates 7 times higher for Moroccan migrants compared to 
the native Dutch population (Veling et al., 2006). 
 
Ødegaard's (1932) landmark study found a twofold increase in first admission rates for 
schizophrenia amongst Norwegian migrants who moved to the United States compared 
with native-born Americans and Norwegians. He hypothesised that those predisposed to 
schizophrenia were more likely to migrate – a theory known as “selective migration”. 
However, this hypothesis garnered little support as it could not account for the increased 
risk for schizophrenia found among second-generation migrants. Nowadays, possible 
explanations centre on postmigration factors including age, sex, socioeconomic status, 
discrimination, social isolation, trauma and abuse (Hollander et al., 2016). 
 
1.6 Pathophysiological hypotheses. 
 
The contributions of neurochemical alterations and brain abnormalities to the 
pathophysiology of schizophrenia have been studied intensively. 
 
1.6.1 The dopamine hypothesis. 
 
Dopamine is a key neurotransmitter modulating essential functions of the central nervous 
system (CNS) including voluntary movement, reward and higher cognitive functions such 
as memory and goal maintenance (Ledonne & Mercuri, 2017). There are two major classes 
of metabotropic dopamine receptors: D1-like receptors (D1 and D5) which are primarily 
excitatory and D2-like receptors (D2, D3, D4) which are primarily inhibitory (Nikolova, 
Bodgan, & Hariri, 2013). Furthermore, there are three major dopaminergic pathways in the 
CNS: the nigrostriatal pathway (substantia nigra to striatum); the mesolimbic pathway 
(ventral tegmental area (VTA) to nucleus accumbens); and the mesocortical pathway 
(VTA to prefrontal cortex (PFC)). 
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Formulated by van Rossum (1966), the “original dopamine hypothesis” postulated that 
hyperactive dopamine D2 receptor neurotransmission contributes to the symptoms of 
schizophrenia. This premise was based on the observation that first-generation 
antipsychotics, such as chlorpromazine and haloperidol, block D2 receptors and dopamine 
agonists, such as amphetamine and methylphenidate, boast psychotomimetic properties 
(Abi-Dargham & Grace, 2010). 
 
However, this initial hypothesis is problematic for two main reasons: (1) although first-
generation antipsychotics effectively treat positive symptoms, they may exacerbate 
negative and cognitive symptoms and (2) the second-generation antipsychotic clozapine, 
despite having one of the lowest levels of D2 receptor occupancy of all antipsychotic 
drugs, is the most efficacious treatment for chronic schizophrenia (Lawrence, First, & 
Lieberman, 2015; Li, Snyder, & Vanover, 2016). 
 
Impairment in higher cognitive functions, such as working memory, is a severe, enduring 
and core symptom of schizophrenia (Laruelle & Abi-Dargham, 2003). Functional brain 
imaging studies have suggested that these symptoms may be associated with a 
dysfunction of the PFC where the dopamine D1 receptor is abundantly expressed (Tsang 
et al., 2015). Indeed, Sawaguchi and Goldman-Rakic (1994) induced deficits in a 
working memory task by infusing D1 receptor antagonists into the PFC of nonhuman 
primates. Similarly, Müller, von Cramon, and Pollmann (1998) administered human 
participants with either a mixed D1/D2 receptor agonist or a selective D2 agonist and 
noted that the former facilitated working memory whereas the latter had no effect.  
 
The “revised dopamine hypothesis” attempts to account for negative and cognitive 
symptoms as well as positive symptoms. It posits that (1) hyperactivity of dopamine D2 
receptor neurotransmission in the mesolimbic pathway results in the positive symptoms of 
schizophrenia and (2) hypofunctionality of dopamine D1 receptor neurotransmission in the 
mesocortical pathway is responsible for the negative and cognitive symptoms of 
schizophrenia (Brisch et al., 2014; Desbonnet, 2016; Patel, Cherian, Gohil, & Atkinson, 
2014). Moreover, disrupted feedback loops have been implicated in the current hypothesis 
(Weinberger, 1987). Normally, activity in the mesocortical pathway inhibits the 
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mesolimbic pathway whereas in schizophrenia, there is reduced activity in the mesocortical 
pathway which leads to disinhibition and overactivity in the mesolimbic pathway. 
 
1.6.2 The glutamate hypothesis. 
 
Glutamate is the main excitatory neurotransmitter in the CNS (Fatemi & Folsom, 2016). 
Mediated through activation of either ionotropic or metabotropic receptors, glutamatergic 
neural transmission plays a central role in neuronal plasticity, neurotoxicity, development, 
learning and memory (Gasbarri & Pompili, 2014). Three major types of ionotropic 
glutamate receptors can be distinguished: NMDA (N-methyl-D-aspartate), AMPA (α-
amino-3-hydroxyl-5-methyl-4-isoxazole-propionate) and kainic acid. The glutamate 
hypothesis proposes that hypofunction of glutamate signalling, via NMDA receptors, 
particularly in the frontal cortex, is responsible for the development of the positive, 
negative and cognitive symptoms of schizophrenia (Coyle, 2012; Kantrowitz & Javitt, 
2010).  
 
NMDA receptor antagonists, such as phencyclidine (PCP) and ketamine, produce 
psychotomimetic effects in healthy human subjects and experimental animals (Krystal & 
Moghaddam, 2010; Perez & Lodge, 2014) while worsening psychotic symptoms in those 
with schizophrenia (Malhotra et al., 1997). Additionally, administration of ketamine at 
subanaesthetic doses correlates with impaired performance on tasks measuring executive 
functions, spatial and verbal working memory and verbal declarative memory (Krystal et 
al., 2000; Rowland et al., 2005). Garnering further support for this hypothesis, NMDA 
receptor deficits have been observed in post-mortem brain tissue derived from individuals 
with schizophrenia (Stone et al., 2008) and in the brain tissue of those living with the 
disorder using single-photon emission tomography (SPET) imaging (Pilowsky et al., 
2006). Another imaging technique, proton magnetic resonance imaging (¹H-MRS), has 
evidenced decreased in vivo glutamate levels in the medial frontal brain region of those 
with schizophrenia when compared to healthy individuals (Marsman et al., 2013).  
 
1.6.3 The GABA hypothesis. 
 
In comparison to glutamate, gamma-aminobutyric acid (GABA) is the main inhibitory 
neurotransmitter in the CNS (Fatemi & Folsom, 2016). Acting on either ionotropic 
25 
(GABAA) or metabotropic (GABAB) receptors, GABA is implicated in cortical maturation, 
synaptic plasticity, and cognition (Ebenezer, 2015). An abundance of evidence indicates 
that dysfunctional GABAergic inhibition and the consequent imbalance between excitation 
and inhibition in the cerebral cortex is linked to schizophrenia (Gonzalez-Burgos & Lewis, 
2012; Lewis, Curley, Glausier, & Volk, 2012; Nakazawa et al., 2012).  
 
Postmortem brain studies of those with schizophrenia have consistently shown that 
glutamic acid decarboxylase 67 (GAD67), the enzyme that converts glutamate to GABA, 
is reduced in a subpopulation of GABAergic neurons (Guidotti et al., 2000; Hashimoto et 
al., 2003, 2008; Volk, Austin, Pierri, Sampson, & Lewis, 2000). In particular, GAD67 is 
reduced in about 50% of parvalbumin (PV)-expressing GABA interneurons in layer 2/3 of 
the PFC (Hashimoto et al., 2003). Reduced concentrations of the transporter protein 
GABA-transporter-1 (GAT-1), which is responsible for GABA reuptake in the presynaptic 
neuron (Volk et al., 2002; Woo, Whitehead, Melchitzky, & Lewis, 1998), and increased 
expression of the α2 subunits of the GABAA receptor, which mediates most of GABA’s 
physiological activities, have additionally been observed in the brain tissue of 
schizophrenia patients (Sieghart et al., 1999).  
 
Ultimately, GABA interneurons play a pivotal role in the brain’s rhythm-generating 
networks, where synchrony of neural oscillations is essential for memory, perception and 
consciousness (Uhlhaas & Singer, 2010). GABA abnormalities may instigate alterations in 
neural synchrony, aberrant neural oscillations in the gamma frequency band and working 
memory impairments, resembling those observed in schizophrenia (Yang & Tsai, 2017). 
 
1.6.4 Dopamine, glutamate and GABA: A revised hypothesis. 
 
Recent evidence increasingly supports a primarily glutamatergic and GABAergic 
dysfunction in schizophrenia, with dopaminergic imbalance as a secondary consequence.  
 
Incoming activity from glutamate neurons in the PFC is modulated by GABAergic 
interneurons which in turn, innervate glutamate pyramidal neurons that project to the VTA 
(Linden, 2011). In healthy individuals, excitation and inhibition via glutamate and GABA, 
respectively, are sufficiently balanced in the system. In schizophrenia, glutamate released 
in the PFC acts on hypofunctional NMDA receptors on PV-expressing GABA 
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interneurons. This results in a reduced release of GABA on the dendrites of glutamate 
pyramidal neurons in the cortex, leading to downstream disinhibition of glutamate release 
in the VTA. The increased glutamate released in the VTA stimulates the dopaminergic 
mesolimbic pathway, enhancing dopamine production (Ebenezer, 2015).  
 
Belforte et al. (2010) performed a restricted deletion of the NMDA receptor in 
corticolimbic interneurons in early postnatal and post-adolescent mice. As well as 
producing schizophrenia-related symptoms, this resulted in reduced expression of GAD67 
and parvalbumin; disinhibition of cortical excitatory neurons; and reduced neuronal 
synchrony in early postnatal but not post-adolescent mice. Therefore, along with secondary 
dopaminergic alterations, NMDA hypofunction early in life may predispose individuals to 
develop psychotic symptoms in adolescence.  
 
1.6.5 The neurodevelopmental hypothesis. 
 
The neurodevelopmental hypothesis of schizophrenia states that abnormal brain 
development during the prenatal and perinatal periods, resulting from genetic and 
environmental factors, underlies the later emergence of psychosis during adulthood 
(McGrath, Féron, Burne, Mackay-Sim, & Eyles, 2003). 
 
Consistent with this view, a multitude of brain abnormalities have been documented in the 
prodromal and early stages of schizophrenia which are similar to, but milder than, those 
seen in the late stages of the disorder (Chung & Cannon, 2015). Structural magnetic 
resonance imaging (MRI) studies have reported evidence of grey matter volume loss and 
cortical thinning across thalamocortical circuitry; gyrification abnormalities; and 
enlargement of the lateral ventricles throughout the prodromal, first-episode and chronic 
course of schizophrenia (Dietsche, Kircher, & Falkenberg, 2017; Gao et al., 2018; 
Sasabayashi et al., 2017). Interestingly, formal thought disorders and hallucinations are 
correlated with grey matter volume loss in the superior temporal lobe while functioning 
correlates with volume loss in the left PFC (Onay, Yapıcı Eser, Ulaşoğlu Yıldız, Aslan, & 
Talı, 2017). 
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Anatomical and functional connectivity alterations have also been demonstrated across the 
various stages of schizophrenia. Anatomically, there is disconnectivity and lack of 
alignment in white matter tracts in frontal and temporoparietal brain regions whereas 
functionally, there is aberrant activity of the default mode network (DMN), numerous 
cognitive control networks and several independent brain regions (Nelson, Bassett, 
Camchong, Bullmore, & Lim, 2017). White matter pathology has been implicated in these 
connectivity alterations. For example, reduced oligodendrocytes - which synthesise myelin 
- were discovered in diffusion tensor imaging (DTI) and post-mortem studies. In addition, 
recent evidence links fronto-temporal abnormalities to specific symptoms of 
schizophrenia; predominantly auditory verbal hallucinations (Oestreich, McCarthy-Jones, 
Whitford, & Bank, 2016). 
 
1.7 Cognitive impairment in schizophrenia. 
 
Cognitive deficits are a hallmark feature of schizophrenia with approximately 80% of 
diagnosed individuals experiencing either neurocognitive or social cognitive deficits or 
both. (Paquin, Wilson, Cellard, Lecomte, & Potvin, 2014). Neurocognition is the ability to 
effectively perceive, attend to and remember information whereas social cognition focuses 
on how people process, store and apply information about other people and social 
situations. Herein, the term “cognition” will be used to refer to both neurocognition and 
social cognition.  
 
In general, individuals with schizophrenia perform, on average, 1 standard deviation below 
HCs on a range of cognitive tasks (Dickinson, Ramsey, & Gold, 2007). The neurocognitive 
domains typically affected include verbal memory, working memory, attention and 
processing speed and executive functions whereas emotion recognition (the ability to 
perceive and recognise facial emotion expressions), theory of mind (the ability to infer 
others’ beliefs and emotions), social perception and knowledge (the ability to detect and 
comprehend social cues with respect to social context) and attributional style (attribution of 
causes of events to the self, others, or the environment) are the social cognitive domains 
most affected (Paquin, Lecomte, & Potvin, 2017). Whether cognitive impairment in 
schizophrenia constitutes a specific deficit to domains or a generalised deficit across 
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domains is a debated issue, although it is likely that cognitive impairments in specific 
domains are superimposed on a more general cognitive deficit (Cassetta & Goghari, 2016). 
 
Interest in the cognitive impairments of schizophrenia is growing, driven largely by 
findings suggesting that these impairments are better predictors of functional outcome than 
positive or negative symptoms (Green, 1996; Harvey et al., 1998). Specifically, cognitive 
deficits have been linked to worse functional outcomes such as poor self-care, decreased 
ability to live independently, poor social skills, inability to maintain successful 
employment and poor compliance with medication regimens (Lepage, Bodnar, & Bowie, 
2014). Effect sizes for the associations between cognitive impairments and functional 
deficits are typically in the medium range for specific domains although larger effect 
sizes are possible for summary scores (Green, Kern, Braff, & Mintz, 2000). 
 
A meta-analysis by Fett et al. (2011) found that social cognition explained 16% of the 
variance in community functioning while neurocognition explained only 6%. Community 
functioning was most strongly associated with theory of mind (r = 0.48) followed by social 
perception and knowledge (r = 0.41), verbal fluency (r = 0.32) and emotion perception and 
processing (r = 0.31). Also, Schmidt, Mueller, and Roder (2011) conducted a review of 15 
studies and concluded that social cognition acts as a mediator between neurocognition and 
functional outcomes. Specifically, social knowledge (mean effect size of 0.28) and social 
perception (mean effect size of 0.21) produced the largest effect sizes for explaining this 
mediation effect. 
 
1.8 The clinical high-risk state for psychosis. 
 
Over the last few decades, the concept of a clinical high-risk (CHR) state for psychosis 
(also known as the “at-risk mental state” (ARMS), “prodromal” and “ultra-high risk” 
(UHR) state) has evolved to capture the prodromal phase of schizophrenia (Fusar-Poli et 
al., 2013). Alongside APS, the CHR state is characterised by a constellation of other 
clinical signs including negative symptoms, mood symptoms, cognitive deficits and 
functional decline (Tandon et al., 2009). 
 
Studies of CHR individuals have been increasingly common, in part due to the potential 
benefits of early intervention and the opportunity to study the “near-psychotic” state 
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without the confounding effects of long-term medication use and chronicity. This is 
evidenced by the recent inclusion of “Attenuated Psychosis Syndrome” in the appendix 
(Section 3) of the DSM-5 as a condition for further study (Sisti & Calkins, 2016). 
 
Two broad sets of CHR criteria currently prevail: the UHR and BS criteria. Whereas the 
UHR criteria detect psychosis risk in the late prodromal phase when functioning is 
somewhat compromised, the BS criteria detect early psychosis risk, ideally before 
functional impairments arise. 
 
UHR criteria were developed and validated within the Personal Assessment and Crisis 
Evaluation (PACE) Clinic by Yung et al. (1996) in Melbourne, Australia to identify help-
seeking individuals at imminent risk of psychosis, i.e., individuals at risk for developing a 
first-episode within the next 12 months. Inclusion requires the presence of one or more of 
the following: APS; brief limited intermittent psychotic symptoms (BLIPS); and trait 
vulnerability plus a marked decline in psychosocial functioning (Genetic Risk and 
Deterioration syndrome: GRD), with the former constituting the most common UHR 
group. Several studies have since validated the UHR criteria, finding that those who meet 
the criteria have a high risk of developing psychosis over 1–2.5 years, with rates in the 
range of 8% to 54% (Miller et al., 2002; Morrison et al., 2012). Specifically, Fusar-Poli et 
al. (2016) found that transition risk in the BLIPS subgroup was higher than in the APS 
subgroup while there was no prognostic difference between the GRD subgroup and 
individuals not at CHR for psychosis, raising concerns about the validity of the GRD 
subgroup. 
 
Different measures have been created to assess UHR criteria: the Comprehensive 
Assessment of At-Risk Mental States (CAARMS); the Structured Interview for Prodromal 
Syndromes (SIPS) and the companion Scale of Prodromal Symptoms (SOPS); the Basel 
Screening Instrument for Psychosis (BSIP); the Early Recognition Inventory for the 
Retrospective Assessment of the Onset of Schizophrenia (ERIraos); and a self-rating 
prodromal screening questionnaire (Loewy, Bearden, Johnson, Raine, & Cannon, 2005). 
Developed by Yung et al. (2005) at the PACE clinic, the CAARMS is widely used in 
Australia, Asia and Europe whereas the SIPS/SOPS, developed by Miller et al. (2003), is 
commonly used in North America and Europe. The ERIroas, now largely used in German 
and Italian studies, was developed by Häfner et al. (1992) to assess schizophrenia onset 
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retrospectively and later, Riecher-Rössler et al. (2007) created the BSIP in the Early 
Detection of Psychosis Clinic in Basel.  
 
In contrast, BS are defined as subtle, subclinical, self-experienced disturbances in drive, 
stress tolerance, affect, attention, memory, thinking, speech, perception and motor action 
(Schultze-Lutter & Theodoridou, 2017). These symptoms, often noticed years before the 
onset of psychosis, are thought to be the earliest perceivable signs of the neurobiological 
disturbance underlying the development of psychosis, hence the term “basic” (Huber & 
Gross, 1989). Unlike UHR criteria, BS are not necessarily observable by others; are 
independent of unusual thought content and reality testing; and individuals have full 
insight into the symptoms’ psychopathological nature. 
 
Initially, BS were assessed using the Bonn Scale for the Assessment of Basic Symptoms 
(BSABS; Huber & Gross, 1989). Shorter versions of the scale were later developed – the 
Schizophrenia Proneness Instrument, Adult version (SPI-A; Schultze-Lutter, Addington, 
Ruhrmann, & Klosterkötter, 2007) for adults and the Schizophrenia Proneness Instrument, 
Child and Youth version (SPI-CY; Schultze-Lutter, Marshall, & Koch, 2012) for children 
and adolescents. While the BSABS only allows a rating of presence, the SPI-A and the 
SPI-CY also allow a frequency-based severity rating based on the past 3 months. Out of 
the BS evaluated on the SPI-A and the SPI-CY, which are both characteristic and 
uncharacteristic of psychosis, there can be derived 2 scales to evaluate specifically the 
characteristic BS: the Cognitive Disturbances scale (COGDIS) and the Cognitive-
Perceptive Basic Symptoms scale (COPER). 
 
Specifically, the COGDIS subset of BS seems to indicate a more imminent risk of 
psychosis compared to the COPER subset, with 25.3% of participants meeting COGDIS 
criteria transitioning to psychosis at 1 year following baseline assessment compared to 
14.4% of those meeting COPER criteria (Schultze-Lutter et al., 2015).  
 
Informed by such findings, the European Psychiatric Association issued guidelines 
supporting the use of BS criteria, in particular COGDIS, along with APS and BLIPS UHR 
criteria, for early detection of psychosis. 
 
1.9 Outcomes in the CHR group. 
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Transition to psychosis in CHRs has markedly declined in recent years. The 2 year risk of 
transition to psychosis from an initial CHR state has shifted from an early 30% (Fusar-Poli 
et al., 2012a) to the current 20% (Fusar-Poli et al., 2016). This phenomenon may be 
explained by effective early intervention, earlier referral or inclusion of false positives (Lee 
et al., 2014). In addition, Simon et al. (2013) carried out a meta-analysis of remission rates 
and reported that 73% of 773 CHR subjects did not transition to psychosis during a 2-year 
follow-up. Of these, 46% fully remitted from their APS, corresponding to clinical 
remission in 35%. Thus, CHR nonconverters are a heterogeneous group comprising 
individuals who later remit from an initial CHR state and those who do not remit and 
continue to experience APS. 
 
Lin et al. (2011) found that, among CHRs with the poorest functional outcome, only 49% 
converted to psychosis. Since such a large proportion of nonconverters continue to report 
disability in multiple fields, it is evident that intervention should not be limited only to 
those with emerging psychosis. Although CHR studies have widely focused on transition 
to psychosis as the main outcome of interest, this arbitrary threshold, based entirely on 
positive symptoms, may be suboptimal for identifying individuals truly at risk of poor 
long-term outcome. Increasingly, evidence suggests that neurocognitive and social 
cognitive performance, functioning and a variety of clinical symptoms at baseline are of 
critical importance when predicting long-term functional outcome.  
 
1.9.1 Cognition. 
 
Cognitive deficits generally manifest in the premorbid phase of schizophrenia, increase in 
severity from the prodrome to the first psychotic episode and remain relatively stable 
thereafter (Corigliano et al., 2014). Indeed, Giuliano et al. (2012) revealed that CHRs had 
small-to-medium impairments (effect sizes from -0.26 to - 0.67) across nine cognitive 
domains, intermediate in magnitude between healthy control (HC) and first episode 
psychosis (FEP) samples. More recently, Seidman et al. (2016) found that CHR 
participants engaged in the North American Prodrome Longitudinal Study (NAPLS 2) 
performed significantly worse than HCs on 19 neuropsychological tests assessing four 
factors derived from factor analysis: executive and visuospatial abilities, verbal abilities, 
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attention and working memory abilities and declarative memory abilities. Certainly, 
deficits in a diffuse range of cognitive domains have been reported in CHR samples, the 
most pronounced of which are described in detail below.  
 
1.9.1.1 Working memory. 
 
Working memory refers to the cognitive function to retain and mentally manipulate 
information over a short period of time. In a meta-analysis by Fusar-Poli et al. (2012b), 
CHR participants were reportedly impaired on working memory relative to HCs, with an 
effect size of 0.36. This impairment became even more marked in those CHRs who 
subsequently transitioned to psychosis. Utilising the Self Ordered Pointing Task (SOPT) - 
a test of working memory – and BS criteria, Frommann et al. (2011) found that deficits in 
working memory were more pronounced in the late prodromal phase compared to the early 
prodromal phase. Other established measures of working memory include n-back and digit 
sequencing tests. 
 
Goghari et al. (2014) observed an association between impaired spatial working memory 
performance and lower global functioning as measured by the Global Assessment of 
Functioning (GAF) scale. Furthermore, Liu et al. (2018) observed that, within the salience 
network, working memory demand related resting-state functional connectivity (FC) 
between the right insula and thalamus varied among controls, remitters and non-remitters. 
Controls had low FC at low demand and high FC at high demand; remitters had high FC at 
low demand and low FC at high demand; and non-remitters had high FC in both demands. 
Overall, the CHR state was associated with functional dysconnectivity.  
 
1.9.1.2 Processing speed. 
 
Processing speed refers to the pace at which individuals are able to perceive information, 
make sense of that information and then respond. Reduced processing speed is reported to 
be the most sensitive discriminator of CHR individuals from controls. Consistent with 
previous studies, Bang et al. (2015) found that processing speed in CHRs was decreased to 
the level of those with FES. Furthermore, Kelleher, Clarke, Rawdon, Murphy, and Cannon 
(2013a) found that non-help-seeking community-based young adolescents who met criteria 
for prodromal syndromes performed significantly more poorly than HCs on three measures 
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of processing speed: the Trail Making Test-A (TMT-A), the Trail Making Test-B (TMT-B) 
and the Brief Assessment of Cognition in Schizophrenia Symbol Coding task (BACS-SC).  
 
Michel, Ruhrmann, Schimmelmann, Klosterkötter, and Schultze-Lutter (2014) investigated 
potential predictors of psychosis in CHRs over 24 months and found that psychosis 
transition risk was highest in the presence of APS criteria, COGDIS criteria and a 
processing speed deficit. Among CHRs, processing speed deficits at baseline predict poor 
social outcome over a follow-up period of 3 to 5 years (Carrión et al., 2013) and correlate 
strongly with self-perceived impairments in stress tolerance cross-sectionally (Schultze-
Lutter et al., 2007). 
 
Specifically, processing speed deficits may point to aberrant integration of whole brain 
connectivity, rather than indexing impairment in discrete neural networks (Kelleher et al., 
2013a) 
 
1.9.1.3 Attention. 
 
Attention refers to a state of awareness in which the senses are focused exclusively and 
selectively on particular aspects of the environment. Hou et al. (2016) found that 
performance on the Stroop Colour and Word Test (SCWT) measure of attention gradually 
decreased from the HC, first degree relatives of patients not fulfilling UHR criteria (FDR), 
FES to CHR groups. However, following a meta-analysis of 32 studies, Hauser et al. 
(2017) noted that, while a second measure of attention - the Continuous Performance Test 
(CPT) - differentiated between CHR and HCs in the domain of attention/vigilance, the 
SCWT did not. Utilising the CPT – Identical Pairs (CPT-IP), Torgalsbøen, Mohn, 
Czajkowski, and Rund (2015), found that attention/vigilance at baseline was a significant 
predictor of social functioning 2 years later, while Lam et al. (2018) stated that changes in 
attention accounted for longitudinal changes in social and occupational functioning over a 
24-month follow-up period. 
 
Rapid orienting of attention to events that are unexpected and contextually deviant is 
commonly associated with the event related potential (ERP) component P3a or novelty P3. 
This component, peaking around 300 milliseconds after stimulus onset at fronto-central 
scalp electrodes, is reduced in amplitude in CHRs (del Re et al., 2015). 
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1.9.1.4 Motor speed. 
 
A number of motor abnormalities have been proposed as core features of psychosis risk, 
including Parkinsonism, spontaneous dyskinesia, psychomotor slowing and neurological 
soft signs (Walther & Mittal, 2017). 
 
Gschwandtner et al. (2006) used a fine motor function test battery comprising five different 
subdomains: steadiness, precision steadiness, aiming, tapping and inserting long and short 
pins. CHR individuals performed below HCs in all subdomains, predominantly in dexterity 
and velocity. Similarly, Lencz et al. (2006) measured motor speed with the TMT-A, the 
Finger Tapping Test and the Grooved Pegboard Test and reported a z-score deficit > 1 
relative to the HC group mean. Although the TMT-A is categorised as a measure of 
processing speed, it can also serve as an index of motor speed due to its low cognitive load. 
 
Giuliano et al. (2012), on the other hand, did not find reliable deficits in fine motor speed. 
The relevant studies in this review only contributed data on the Finger Tapping Test, 
leading to the conclusion that a more comprehensive battery is likely to reveal 
abnormalities. Moreover, on examination of gross motor behaviour using innovative video 
analysis software during a standard clinical interview, Dean, Samson, Newberry, and 
Mittal (2017) did not find evidence of psychomotor slowing. Rather, the CHR group 
showed greater speed of body movements compared to HCs, suggesting that psychomotor 
slowing is subtle during the CHR period. For example, Dean and Mittal (2015) found that 
CHR individuals were significantly impaired relative to HCs in the ability to scale velocity 
using pen movements on a digital tablet, possibly reflecting some rigidity or Parkinsonism. 
 
Over a follow-up period of 3-5 years, motor disturbances at baseline are reportedly 
predictive of later role outcome, independent of conversion to psychosis (Carrión et al., 
2013). Furthermore, Fryer et al. (2018) collected functional MRI data during Go/NoGo 
task performance from CHR youth, individuals with early illness schizophrenia (ESZ) and 
HCs. Compared to HCs, CHR and ESZ groups had slower and more variable reaction 
times on Go trials and reduced NoGo activation in right inferior frontal gyrus (RIFG) and 
anterior cingulate cortex (ACC) - regions associated with response conflict and response 
inhibition.  
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1.9.1.5 Verbal learning and memory. 
 
Verbal learning is the process of actively memorising new material while verbal memory 
refers to the temporary maintenance and manipulation of verbal information. Standard word 
lists (California/Auditory/Rey/Hopkins Verbal Learning Test) and subscales of the Wechsler 
Memory Scale (WMS) have been used to investigate verbal learning and memory. Non-
remitters present with significantly worse immediate/delayed verbal memory, as measured 
by the California Verbal Learning Test (CVLT), when compared to HCs (Lee et al., 2014). 
Interestingly, when remitters and non-remitters comprised one group of nonconverters, this 
difference disappeared for delayed verbal memory but remained for immediate verbal 
memory. In contrast to FEP studies, the low CVLT scores reported in previous CHR studies 
appear to be driven primarily by impairments in the rate of learning rather than by attentional 
processes. Egloff et al. (2018) indicated that, while FEP patients were impaired in both initial 
recall and learning rate, ARMS patients were only impaired in learning rate on the CVLT. 
 
Niendam et al. (2006) detected pronounced verbal learning and memory deficits in CHR 
individuals using child and adult versions of the CVLT-II and the WMS-III. Furthermore, 
these deficits were predictive of current social functioning, irrespective of negative or 
positive symptom severity. Similarly, Cornblatt et al. (2015) suggested that, for CHR 
individuals, verbal memory along with disorganised communication, suspiciousness and a 
decline in social functioning were the best predictors of later transition to psychosis. They 
claimed that this model increased the risk of positive prediction from 30% with the CHR 
criteria alone to 81.8%. 
 
Specifically, deficits in verbal learning and memory may be related to a reduced connectivity 
between the hippocampus and PFC secondary to a reduction of hippocampal volume 
(Antoniades et al., 2018). However, it is currently unclear how hippocampal volume 
reductions impact on, and therefore precede, these connectivity alterations.  
 
1.9.1.6 Verbal fluency. 
 
Verbal fluency is the ability to retrieve and express words compatible with required criteria. 
It can be measured by semantic (category) and phonological (letter) fluency tasks. Deficits 
36 
in this domain reportedly precede psychosis onset by up to 30 months (Lencz et al., 2006). 
In schizophrenia, semantic fluency seems to be impaired to a greater extent than 
phonological fluency – a finding replicated in CHRs. Magaud et al. (2010) found that CHR 
individuals had a lower mean total semantic fluency score than help-seeking controls. This 
effect remained significant when each semantic category (animals and fruits) was considered 
separately. By contrast, no differences were observed between CHRs and help-seeking 
controls in total phonological fluency scores or when each letter (P and R) was considered 
separately. Additionally, although Lee et al. (2014) did not detect differences at baseline 
between remitters and non-remitters for performance on a semantic fluency task, the 
performance of remitters improved whereas the performance of non-remitters declined over 
the 2-year follow up period. 
 
Lower scores on the Controlled Word Association Test (COWAT) measure of verbal fluency 
at baseline have been found to predict both poor functioning and lower scores on the Scale 
of Assessment for Negative Symptoms (SANS) at follow-up an average 7.26 years later (Lin 
et al., 2011). During verbal fluency performance, CHRs display reduced activation in 
prefrontal brain regions and reduced prefrontal-temporal functional connectivity, which 
may, in turn, be driven by changes in subcortical glutamate function (Allen et al., 2015; 
Holper et al., 2015). 
 
1.9.1.7 Executive function. 
 
Executive functions are complex, higher order processes involved in the planning, 
organisation, regulation and monitoring of goal-directed behaviour. Deficits in executive 
control functioning are already present in the early prodrome of psychosis relative to HCs 
(Frommann et al., 2011). Moreover, this deficit is greater than - and independent from - 
impairments in other cognitive domains. Simon et al. (2012) administered a comprehensive 
neuropsychological test battery to CHRs and found that executive functions showed the 
largest impairments, although they did not predict later conversion. 
 
Riecher-Rössler et al. (2009) were the first to identify a risk profile for transition to psychosis 
including not only clinical symptomatology but also a neurocognitive variable: 
suspiciousness, anhedonia/asociality and performance on a measure of executive 
functioning. With this combination, transition to psychosis could be predicted with a 
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sensitivity of 83.3% and a specificity of 79.3%. In other words, 15 of 18 converters and 23 
of 29 nonconverters could be correctly predicted. Further research has also shown that 
executive functioning deficits at baseline significantly predict both role and social 
functioning at 1-year follow-up (Eslami, Jahshan, & Cadenhead, 2011). 
 
Utilising the TMT-B to measure executive function, Koutsouleris et al. (2010) observed 
impaired performance in CHRs versus HCs. As well as relating this impairment to a 
volumetric pattern covering mainly prefrontal, premotor, occipital and cerebellar brain 
regions, they linked it to an attenuated structural connectivity between the prefrontal and 
limbic–paralimbic cortices. 
 
1.9.2 Social cognition. 
 
Fusar-Poli et al. (2012b), in the first comprehensive meta-analysis of cognitive functioning 
in CHR subjects, found significant deficits in social cognition compared to HCs despite the 
different measures used across studies. Furthermore, the magnitude of this deficit exceeded 
any of the examined neurocognitive domains. In a later meta-analysis (van Donkersgoed, 
Wunderink, Nieboer, Aleman, & Pijnenborg, 2015), CHRs presented with moderate 
deficits in affect recognition and affect discrimination in faces as well as in voices and in 
verbal theory of mind compared to HCs. Although a moderate effect was also found for 
visual theory of mind, this was not significant.  
 
Additionally, Corcoran et al. (2015) found evidence of emotion recognition deficits, as 
measured by the Penn Emotion Recognition task (ER40), in CHR individuals who later 
transitioned to schizophrenia. Specifically, these deficits were driven by a decrease in 
discrimination of negative expressions portraying fear and anger from neutral expressions. 
Mean emotion recognition scores obtained by these CHR individuals were at or below 
those observed in normally developing 10-year-olds whereas CHRs without transition and 
HCs showed age-appropriate performance levels. Moreover, face emotion processing in 
combination with negative symptoms produced the best classification model for 
schizophrenia onset, with an accuracy of 96%. Kohler et al. (2014) also used the ER40, 
revealing comparable impairments in recognition of happy, angry and fearful expressions 
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for CHRs and schizophrenia subjects. Participants with genetic risk for schizophrenia were 
less impaired, showing reduced recognition of fearful expressions.  
 
Conversely, while findings from baseline measures of the NAPLS 2 cohort suggested that 
CHRs were significantly impaired in theory of mind and emotion recognition, the emotion 
recognition deficits did not remain statistically significant when controlling for age and IQ 
(Barbato et al., 2015). Also, Glenthøj et al. (2018) reported no significant group differences 
in response latency on any of the six emotion recognition tasks from the CANTAB Battery 
(CANTAB ERT) or the total score between CHRs and HCs, suggesting that both groups 
use a similar level of automatic processing. 
 
Contrary to previous findings in individuals with schizophrenia, social cognition does not 
seem to mediate the pathway from neurocognition to functional outcome in those at CHR 
for psychosis (Barbato et al., 2013). The association of social cognitive abilities with 
functioning and social skills was examined by Glenthøj et al. (2016). CHRs demonstrated 
decrements in both theory of mind and emotion recognition tasks. In particular, CHRs 
were selectively impaired at recognising the negative emotions of disgust, anger and fear. 
While theory of mind ability was associated with self-reported functioning, aspects of 
emotion recognition were associated with role functioning and social skill performance. In 
comparison, although Cotter et al. (2017) showed that poorer performance on a visual 
theory of mind task was associated with poorer overall functioning in CHRs, no 
association was evident between emotion recognition and functioning. However, their 
measure of emotion recognition incorporated a narrow range of expressions, possibly 
lowering sensitivity.  
 
When inferring other’s beliefs and emotions, CHR and schizophrenia subjects exhibit 
hyperactivity in the superior temporal sulcus (STS) and hypoactivity in the inferior frontal 
gyrus (IFG). While the schizophrenia group display higher activity in the left STS 
compared to both HCs and CHRs when inferring other’s beliefs, the CHR group show 
higher activity in this region when inferring other’s emotions (Takano et al., 2017). 
Hyperactivity in the STS is also evident during emotion recognition in CHRs in addition to 
hyperactivity in the amygdala and posterior cingulate (Haut et al., 2017). 
 
1.9.3 Clinical and functional characteristics. 
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In terms of clinical characteristics, evidence suggests that negative, positive and 
disorganised symptoms (Brandizzi et al., 2015; Eslami et al., 2011; Salokangas et al., 
2014; Schlosser et al., 2012) at baseline predict CHR participants’ functional outcome at 
follow-up. Brandizzi et al. (2015) found that the suicidality and self-harm CAARMS 
subscale emerged as the strongest predictor of good, versus poor, functional outcome in 
univariate analyses while CAARMS total score significantly contributed to the final 
prediction model. Although Salokangas et al. (2014) found that positive, negative and 
disorganised symptoms associated strongly with poor functioning at baseline, only 
negative symptoms were retained in the model predicting functioning from 9-18 months. 
 
Functioning prior to disorder onset is considered one of the strongest predictors of later 
functional outcome in subjects with chronic schizophrenia (Barajas et al., 2013), FEP 
(Chang et al., 2013) and those at CHR for psychosis. Brandizzi et al. (2015) found that 
GAF scores and employment status at baseline contributed to the prediction of functional 
outcome in CHR subjects at 6 years. As expected, better functioning at baseline predicted 
good functional outcome. Similarly, impaired social and role (academic/occupational) 
functioning at baseline, as measured with the Global Functioning: Social (GF: Social) and 
Global Functioning: Role (GF: Role) scales, have previously been shown to predict poor 
functioning over a follow-up period of 3-5 years (Carrión et al., 2013). Carrión et al. 
(2013) also noted that CHRs with good social outcome showed a modest improvement in 
social functioning compared to those with poor social outcome (23.6% vs -5.0%) and 
CHRs with good role outcome showed a modest improvement in role functioning 
compared to those with poor role outcome (61.4% vs -9.1%). 
 
Additionally, poor premorbid psychosocial adjustment, as measured by the Premorbid 
Adjustment Scale (PAS), has been shown to predict low GAF scores over a follow-up 
period of 18 months (Salokangas et al., 2014). Adolescence adjustment (12-18 years) - 
especially subscales relating to social and sociosexual development and school adaptation - 
was found to have stronger associations with functioning than childhood adjustment (up to 
11 years). On the other hand, no differences in association were apparent between early 
(12-15 years) and late (16-18 years) adolescence adjustment and functioning. 
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Conversely, Lin et al. (2011) did not find an association between baseline GAF scores and 
later poor outcome as defined by low scores on the Quality of Life Scale (QLS) and the 
Social and Occupational Functioning Assessment Scale (SOFAS). 
 
Notably, the GAF score is based on both symptomatic severity and functional impairment, 
whichever is more severe. Therefore, under certain circumstances, functional impairment 
may contribute minimal information. In contrast, the GF: Social and GF: Role scales refer 
only to functioning, preventing conflation with symptom severity. 
 
1.10 Aims of this thesis. 
 
Current understanding of the CHR state for psychosis has been based almost entirely on 
studies of help-seeking participants. However, little-to-nothing is known about members of 
the general population who meet CHR criteria but do not contact specialised early 
detection services, meaning that current data collected on the CHR state is unrepresentative 
of the total population. 
 
Mills, Fusar-Poli, Morgan, Azis, and McGuire (2017) collected cross‐sectional data from a 
general population sample (N = 208) and found that 18 participants (8.7%) met UHR 
criteria, 16 (7.7%) met BS criteria and four met both. Community CHR individuals were 
similar to help-seeking individuals in age, gender, ethnicity, employment status, years of 
education, history of childhood trauma and current cannabis use, but were more likely to 
be first-generation migrants. Also, positive symptoms, negative symptoms and general 
psychopathology were less severe in the community, versus help-seeking, CHR sample 
while levels of social and occupational functioning were higher. However, they had poorer 
functioning than non‐CHR subjects. Importantly, approximately half of the community 
CHR sample had sought help for a psychological or emotional problem in the past year 
from a non-specialised agency, counteracting the view that these individuals are “non‐help‐
seeking”. 
 
Clearly, the general population comprises an important target group in CHR research. 
Improved identification of CHRs in the general population would ensure that these 
individuals have better access to specialised mental health interventions. Although an 
online screening approach would provide an efficient, accessible and cost-effective method 
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to detect CHR-participants at the population-level, the utility of such an approach is largely 
unexplored.  
 
Moreover, in light of declining transition rates and the heterogeneity of CHR samples, it is 
becoming increasingly important to focus on outcomes other than psychosis transition, such 
as functional status. Despite over 2 decades of preventative research, an understanding of 
the complex factors associated with good and poor functional outcomes in CHR individuals 
remains elusive.  
 
Utilising an online screening approach, to ensure the majority of the CHR sample were 
recruited from the general population, the aim of this thesis is to address the following 
questions:  
 
(1) Can functional and cognitive variables discriminate between CHR individuals and 
HCs at baseline? 
 
(2) What is the relationship between cognitive performance, clinical symptoms and 
functioning in CHR individuals at baseline? 
 
(3) What is the functional outcome of CHR individuals at 6- and 12-month follow-up? 
 
(4) Does functioning remain stable or change over 6- and 12-months? 
 
(5) Can clinical, functional and cognitive variables at baseline discriminate between 
CHR individuals with good functional outcome (GFO) and poor functional 
outcome (PFO) at 6- and 12-months? 
 
(6) What are the baseline predictors of PFO in CHR individuals at 6- and 12-months?  
 
It was hypothesised that: (1) functional and cognitive variables would discriminate 
between CHR individuals and HCs at baseline; (2) cognitive performance would be related 
to clinical symptoms and functioning at baseline; (3) a substantial proportion of CHR 
individuals would have PFO at 6- and 12-months; (4) levels of functioning would remain 
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stable in the PFO group and improve in the GFO group over 6- and 12-months; (5) 
baseline clinical, functional and cognitive variables would discriminate between CHR 
individuals with GFO and PFO at 6- and 12-months; and (6) a combination of baseline 
clinical, functional and cognitive variables would provide the best prediction of functional 
outcome at 6- and 12-months. 
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2.0 Methods 
 
2.1 Recruitment and participants. 
 
Data were collected as a part of a Medical Research Council (MRC) funded, longitudinal, 
multisite study entitled “Youth Mental Health Risk and Resilience Study” (YouR-Study; 
Uhlhaas et al., 2017) which aims to identify neurobiological and psychological mechanisms 
and predictors of psychosis-risk. The study was approved by the ethical committees of the 
NHS Research Ethical Committee Glasgow and Greater Clyde and is being carried out 
according to the Research Governance Framework for Health and Community Care (Second 
edition, 2006). The specific YouR-Study protocol utilised in the current study is displayed 
in Figure 1. 
 
In the baseline analyses, 129 CHR individuals (97 females, 32 males) were included. At 6-
month follow-up, data was available for 86 CHR individuals (65 females, 21 males) whilst, 
at 12-month follow-up, data was available for 69 CHR individuals (53 females, 16 males). 
Although these CHR samples were primarily recruited from the general population, eight 
individuals in the baseline analyses, five in the 6-month follow-up analyses and two in the 
12-month follow-up analyses were referred to the study. Also, of note, five individuals in 
the baseline and 6-month follow-up analyses and three individuals in the 12-month follow-
up analyses transitioned to psychosis.  
 
In addition to CHR-participants, 46 CHR-negative (CHR-N) participants who did not meet 
CHR criteria at first baseline clinical assessment and 55 HCs without an Axis I diagnoses 
and/or family history of psychotic disorders were recruited. Follow-up data was available 
for 40 CHR-N participants. The CHR-N group was included to control for psychiatric 
comorbidities associated with the CHR state. 
 
Email invitations, flyers and public transport advertisements were used to direct potential 
CHR and CHR-N participants from the general population to our website (www.your-
study.org.uk). Specifically, email invitations were sent out to colleges and Universities in 
Glasgow and Edinburgh. For potential referrals, NHS-patient services in NHS Greater 
Glasgow and Clyde and NHS Lothian and student counselling services were approached. 
Informed consent for potential referrals was either obtained on-site or participants were 
44 
asked to register online for the study. HCs were recruited from a participant database held 
by the University of Glasgow’s Centre for Cognitive Neuroimaging (CCNi). 
 
General inclusion and exclusion criteria applicable to all groups is shown in Table 1. CHR-
Ns and HCs were also excluded if they had a first degree relative with a diagnosis of 
schizophrenia. 
 
Table 1 
General Inclusion and Exclusion Criteria 
Inclusion Criteria Exclusion Criteria 
Written informed consent An existing neurological 
disorder 
Male or non-pregnant female ≥ 
16 years of age 
> 35 years of age 
 
Normal to corrected vision Metal implants in body parts 
 Pregnancy 
 Suicidal intent  
 
Informed consent for the web screening was provided online, followed by two 
questionnaires to assess psychosis risk: 1) the 16-item version of the prodromal 
questionnaire (PQ-16; Ising et al., 2012) which was developed from the 92-item PQ 
(Loewy et al., 2005) and 2) a 9 item-scale for the assessment of perceptual-cognitive 
anomalies (PCA) generated from existing patient descriptions of cognitive and perceptual 
experiences and the SPI-A. Participants were asked to provide ratings based on experience 
in the last 12 months. In order to qualify for the second part of the study, participants were 
required to positively endorse 6 or more items on the PQ and/or 3 or more items on the 
PCA.  
 
2.2 Baseline clinical assessments. 
 
Participants who met PQ and/or PCA criteria were invited, via email, to participate in the 
second part of the study which involved baseline clinical assessments to ascertain CHR 
status and a baseline cognitive assessment.  
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2.2.1 Demographic and treatment information. 
 
At the beginning of the first baseline clinical assessment, informed consent was obtained. 
Demographic information was collected including gender, age, years of education, 
citizenship and family history. Participants were also asked to discuss any episode of 
physical or mental health illness they had experienced in the last 12 months and whether 
they had received treatment, medication or been admitted to a psychiatric ward for such an 
episode in their lifetime. Suicide risk was assessed and if current suicidality was reported, 
appropriate referrals were made and the participant did not continue in the study.  
 
2.2.2 Assessment of CHR symptoms and criteria. 
 
Two semi-structured interviews – the positive scale of the Comprehensive Assessment of 
At-Risk Mental States (CAARMS; Yung et al., 2005) and 14 items of the Schizophrenia 
Proneness Instrument, Adult version (SPI-A; Schultze-Lutter et al., 2007) - were 
administered by trained research assistants and MSc/PhD level researchers during the 
initial screening to assess psychosis risk. These instruments have shown excellent overall 
inter-rater reliability: 0.85 for the CAARMS and 0.91 for the SPI-A (Fusar-Poli et al., 
2015). 
 
The CAARMS is the dominant method of determining whether participants meet the 
criteria for an at-risk mental state (ARMS). ARMS refer to the cluster of symptoms and 
signs detected by the operationalised ultra-high risk (UHR) criteria. Specifically, 
participants were administered the positive scale of the CAARMS which is designed to 
assess four symptom subscales – unusual thought content, non-bizarre ideas, perceptual 
abnormalities and disorganised speech. Each of these are rated on a 0-6 scale for intensity 
and frequency. In addition, participants rated how distressed they were by these symptoms 
using a scale from 0 (not at all distressed) to 100 (extremely distressed). A positive 
symptom severity score was calculated as the summed scores of the product of intensity 
(0–6) and frequency (0–6) scores of the four subscales. 
 
In order to meet UHR Criteria and be classified into the CHR group, participants must 
have experienced either: (1) a 30% or greater drop in Global Assessment of Functioning 
(GAF) score from a premorbid level, sustained for one month and occurring within the past 
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12 months or (2) chronically low GAF (score of ≤ 50) for the past 12 months or longer. In 
addition, participants must also meet criteria for at least one of the following groups: 
 Group 1: Vulnerability Group - Family history of psychosis in first degree 
relative or Schizotypal Personality Disorder identified in the participant. 
 Group 2: Attenuated Psychosis Group - Individuals who have experienced sub-
threshold (intensity or frequency) positive psychotic symptoms in the past year. 
 Group 3: Brief Limited Intermittent Psychosis Syndrome (BLIPS) Group - 
Those who have experienced short episodes of frank psychotic symptoms within 
the past year that have not lasted longer than a week and have resolved without 
treatment. 
 
Participants were classified into the FEP group if symptom intensity was scored as a 6 on 
either unusual thought content, non-bizarre ideas, or disorganised speech, or 5-6 on 
perceptual abnormalities, with an associated frequency score of 4-6 (at least “3 to 6 times a 
week - more than an hour per occasion”) and with these experiences lasting longer than 
one week. 
 
Two partially overlapping items from the SPI-A were administered: COGDIS which 
assesses nine basic symptoms (BS) of cognitive disturbance and COPER which assesses 10 
cognitive-perceptive BS. Participants were asked to rate the maximum frequency of 
occurrence of these BS within the past 3 months on a 0-9 point scale with scores between 3 
and 6 indicating symptom presence. A score of 7 was given if the symptom had always 
been present at the same severity whereas scores of 8 and 9 indicated that, although the 
symptom was present, there was not sufficient information to give a rating between 0 and 
6. If applicable, the participant was also asked to rate how distressing the BS were on a 
scale from 0 to 100.  
 
Participants were also recruited into the CHR group if they met either COPER or COGDIS 
criteria (see Table 2). To meet COPER criteria, the participant had to report at least one of 
10 cognitive perceptive BS as having first occurred more than 12 months ago with a 
frequency score of 3-6 (at least “several times in a month or weekly”) within the past 3 
months. To meet COGDIS criteria, the participant must have experienced at least two of 
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nine cognitive disturbance BS – five of which are also included in COPER - with a 
frequency score of 3-6 within the past 3 months. 
 
Table 2 
COGDIS and COPER Criteria 
COGDIS Criteria COPER Criteria 
Inability to divide attention Though interference 
Thought interference Thought preservation 
Thought pressure Thought pressure 
Thought blockages Thought blockages 
Disturbance of receptive speech Disturbance of receptive speech 
Disturbance of expressive speech Decreased ability to discriminate between 
ideas/perception, fantasy/true memories 
Unstable ideas of reference Unstable ideas of reference 
Disturbances of abstract thinking Derealisation 
Captivation of attention by details of the 
visual field 
Visual perception disturbances 
 Acoustic perception disturbances 
 
2.2.3 Assessment of functioning. 
 
At the first baseline clinical assessment, overall (global) functioning over the past month 
was assessed using the modified version of the GAF scale included in the Structured 
Interview for Psychosis-Risk Syndromes (SIPS; McGlashan, Walsh, & Woods, 2010). The 
GAF is scored by considering impairments in psychological, social and role functioning. 
The scale is divided into 10 equal 10-point intervals that have clear anchor points with 
scores ranging from 1 to 100 (with 100 indicating superior functioning and 1 representing 
extreme dysfunction).  
 
At the second baseline clinical assessment, Global Functioning: Social (GF: Social) and 
Global Functioning: Role (GF: Role) scales (Cornblatt et al., 2007), broadly derived from 
the traditional GAF scale, were used to measure social and role functioning. These 
complementary scales generate three scores: lowest level of functioning in the past month 
(current functioning), lowest level of functioning over the past year and highest level of 
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functioning over the past year. For both scales, scores range from 1 to 10 where 1 indicates 
extreme dysfunction and 10 represents superior functioning. A score of 6 typically 
characterises UHR participants. The GF: Social scale assesses the quality and quantity of 
the participant’s social contact/interactions with friends and family including conflict, 
intimate relationships and involvement. On the other hand, the GF: Role scale considers 
performance and level of support required in school, university, work or housekeeping, 
depending on the participant’s age. As well as preventing psychiatric symptoms from 
confounding functioning, these scales have shown excellent inter-rater reliability in both 
CHRs and FEPs with an intraclass correlation coefficient for current functioning of 0.85 
for the GF: Social scale and 0.93 for the GF: Role scale (Cornblatt et al., 2007). 
 
2.2.4 Assessment of psychiatric disorders. 
 
Participants were administered the Mini-International Neuropsychiatric Interview (MINI; 
Sheehan et al. 1998) during the second baseline clinical assessment to identify psychiatric 
comorbidity. The MINI is a short, structured diagnostic interview used to assess the 17 
major psychiatric disorders (27 past and current disorders) in the Diagnostic and Statistical 
Manual of Mental Disorders, 4th Edition (DSM–IV; APA, 1994) and the International 
Classification of Diseases, 10th Revision (ICD-10, WHO, 1992). Diagnoses assessed by the 
MINI in the current study were the following: anxiety disorders (panic attack disorder, 
agoraphobia, social phobia, generalised anxiety disorder); mood disorders (episodes of 
major depression, hypomania and mania); eating disorders (anorexia nervosa and bulimia 
nervosa); suicidality; alcohol dependence/abuse; and substance dependence/abuse.  
 
The MINI is organised in diagnostic modules with branching tree logic and based on yes 
and no answers. There are one or two screening questions per disorder which are used to 
rule out the diagnosis when answered negatively. However, if answered positively, 
additional symptom questions are asked, possibly resulting in the diagnosis of a psychiatric 
disorder. 
 
Concurrent validity of the MINI with more extensive structured interviews is good as 
demonstrated by median kappas of 0.67 and 0.63 with the Structured Clinical Interview for 
DSM diagnoses, Patient Version (SCID-P; Sheehan et al., 1997) and the Composite 
International Diagnostic Interview (CIDI; Lecrubier et al., 1997), respectively (Sheehan et 
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al., 1998). The MINI also demonstrates excellent inter-rater reliability (median kappa = 
0.92) and good test-retest reliability (median kappa = 0.78). 
 
2.3 Baseline cognitive assessment. 
 
2.3.1 Brief Assessment of Cognition in Schizophrenia. 
 
Participants were administered a standard cognitive battery: The Brief Assessment of 
Cognition in Schizophrenia (BACS; Keefe et al., 2004). This measure is simple to use, 
requiring only paper, pencils and a stopwatch and takes approximately 35 minutes to 
complete. The BACS assesses multiple domains of cognitive function (see Table 3) 
thought to be effected by schizophrenia and which appear to have clear functional 
relevance (Keefe, 2012). Indeed, Keefe, Poe, Walker, and Harvey (2006) found that the 
BACS composite score was strongly correlated to functioning measures including 
independent living skills (r = 0.45), performance-based assessment of functioning (r = 
0.56) and interview-based assessments of cognition in patients with schizophrenia (r = 
0.48). Also, the BACS exhibits similar sensitivity to the cognitive deficits of schizophrenia 
as a standard 2.5-hour battery (Keefe et al., 2004). 
 
The BACS composite score displays high test-retest reliability in schizophrenia patients 
and HCs (intraclass correlation coefficients > 80) and has a high correlation (r = 0.84, p < 
0.001) with the composite score derived from the CATIE Neurocognitive Test Battery 
(Keefe et al., 2007a, 2007b; Hill et al., 2008). 
 
Table 3 
Neurocognitive Domains Assessed by the BACS 
Cognitive 
Domain 
Task Procedure Measure Range 
Verbal 
Memory 
List 
Learning 
(Version 1) 
Participants are read a list of 15 words 
and then asked to recall as many as 
possible in no particular order. 
Procedure repeated five times. 
Number of 
words recalled 
per trial 
0-75 
50 
Working 
Memory 
Digit 
Sequencing 
Task 
Participants are read randomly ordered 
clusters of numbers which steadily 
increase in trial length. They are asked 
to report numbers in order, from 
lowest to highest. 
Number of 
correct 
responses 
0-28 
Motor 
Speed 
Token 
Motor Task 
Participants are given 100 plastic 
tokens and given 60 seconds to place 
as many as possible in a container, two 
at a time with each hand 
simultaneously. 
Number of 
tokens 
correctly 
placed in the 
container 
0-100 
Verbal 
Fluency 
Semantic 
Fluency 
Participants are asked to name as many 
animals as possible in 60 seconds 
Number of 
animals named 
0 - 
infinity 
 Letter 
Fluency 
In two separate trials, participants are 
given 60 seconds to produce as many 
words as possible beginning with a 
given letter, here F and S. 
Number of 
words 
generated per 
trial 
0 - 
infinity 
Attention 
and 
Processing 
Speed 
Symbol 
Coding 
Participants are given 90 seconds to 
write numerals 1-9 as matches to non-
meaningful symbols on a response 
sheet, as based on a key provided to 
them. 
Number of 
correct items 
0-110 
Executive 
Function 
Tower of 
London 
(Version A) 
Participants are shown two pictures (A 
and B) simultaneously - each showing 
three different-coloured balls arranged 
on three pegs. They then estimate the 
number of times the balls in picture A 
have to be moved in order to match the 
arrangement in picture B. If 
participants respond correctly to all 20 
trials, two additional, harder trials are 
administered. 
Number of 
correct 
responses 
0-22 
 
2.3.2 The Penn Computerized Neurocognitive Battery. 
 
The following three tasks from the Penn Computerized Neurocognitive Battery (CNB; 
Moore, Reise, Gur, Hakonarson, & Gur, 2015) were included in the cognitive assessment: 
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1) Continuous Performance Task; 2) Letter N-Back Test; and 3) Emotion Recognition 
Task. The CNB demonstrates good test-retest reliability and sensitivity to diagnosis (R. E. 
Gur et al., 2007) as well as favourable correlations with traditional paper-pencil batteries in 
those with schizophrenia (R. C. Gur et al., 2001). 
 
The Penn Continuous Performance Test (PCPT; Kurtz, Ragland, Bilker, Gur, & Gur, 2001) 
is a measure of visual attention and vigilance. In this task, a series of red vertical and 
horizontal lines composed of 7-segments flash at a rate of one second each. Specifically, 
the stimulus flashes for 300 milliseconds and a blank page is then displayed for 700 
milliseconds. During this response window, the participant has to press the spacebar when 
the lines form a complete number (initial 3 minutes) or a complete letter (next 3 minutes). 
The total number of true positive responses is recorded as the accuracy score and the 
median response time for true positive responses is selected as a measure of response time 
(RT). 
 
The Penn Letter-N-Back Test (LNB2; Ragland et al., 2002) is a measure of working 
memory. In this task, a continual series of letters flash on screen for 500 milliseconds (one 
at a time) and the participant has an additional 2000 milliseconds to respond by pressing 
the spacebar according to three different rules - known as 0-back, 1-back and 2-back. 
During the 0-back condition, the participant has to press the spacebar whenever the letter 
“X” appears on the screen. During the 1-back condition, the participant is tasked with 
pressing the spacebar whenever the letter on the screen is the same as the previous letter 
(i.e. in the series, “R”, “M”, “M”, the spacebar should be pressed upon appearance of the 
second “M”). During the 2-back condition, a spacebar press is required when the letter 
onscreen matches the letter before the previous letter (i.e. in the series “R”, “M”, “R”, the 
spacebar should be pressed upon appearance of the second “R”). The total number of true 
positive responses is recorded as the accuracy score and the median response time for true 
positive responses is selected as a measure of RT. 
 
The Penn Emotion Recognition Task (ER40; R. C. Gur et al., 2002) is a measure of 
emotion recognition – a key component of social cognition. Participants are presented with 
40 faces (one at a time) and must decide, by a multiple-choice format, whether the actor’s 
face expresses happiness, sadness, anger, fear or no emotion (neutral). There are 4 female 
and 4 male faces for each emotion covering a wide age range and four races (Caucasian, 
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African-American, Asian and Hispanic). The total number of correct responses is used as 
the accuracy score and median response time for correct responses serves as a measure of 
RT. 
 
2.4 Outcome assessment. 
 
Follow-up interviews were conducted approximately 6- and 12-months post-baseline for 
CHR and CHR-N participants. During these two visits, participants were administered the 
positive scale of the CAARMS as well as the GF: Social and GF: Role scales.  
 
CHR participants were divided into two functional outcome groups at 6- and 12-month 
follow-up using the GAF scale: (1) a good functional outcome (GFO) group (GAF score ≥ 
65) and (2) a poor functional outcome (PFO) group (GAF score ≤ 64). The group split at 
the GAF score of 65 was chosen because the 60-70 range corresponds to the presence of 
“some persistent difficultly in social, occupational or school functioning but [the person] 
has some meaningful interpersonal relationships”. GAF scores below 60 indicate moderate 
to severe impairment, whilst scores above 70 signify slight impairment to good function. 
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Figure 1. Flow diagram of the current study protocol  
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2.5 Statistical analyses. 
 
All statistical analyses were performed using SPSS Version 25 and the level of significance 
was set at 0.05 (two-tailed). 
 
BACS and CNB raw scores for each cognitive domain were separated by gender and 
converted into standardized z-scores using the means and standard deviations of gender-
specific HCs. This gender correction was applied in order to address statistically 
significant gender differences in BACS cognitive domain scores previously reported in 
normative data from healthy controls (Keefe et al., 2008). The BACS composite score for 
each participant was calculated by averaging all six z-scores obtained from the primary 
measures and then re-standardising the averaged score in the same way mentioned above 
(Keefe et al., 2004). 
 
Descriptive statistics included mean and standard deviation for continuous variables; 
median and range for ordinal variables; and absolute and relative frequencies for 
categorical variables. Differences in baseline demographic, clinical, functional and 
cognitive characteristics between groups were analysed using one-way ANOVAs for 
continuous variables; non-parametric Kruskal-Wallis H tests for ordinal variables; and chi-
square tests for categorical variables. When the homogeneity of variances assumption was 
violated in one-way ANOVA analyses, Welch’s F was reported. Since the one-way 
ANOVA is considered a robust test against the normality assumption, no alternative tests 
were applied. Wilcoxon signed rank tests were also conducted to ascertain whether 
functioning significantly changed over time within the same CHR subjects. 
 
For cognition analyses, Hochberg’s GT2 test and the Games-Howell test were used as post 
hoc tests for ANOVA analyses and Welch analyses, respectively. Effect sizes for each 
cognitive domain were calculated using Cohen’s d (Cohen, 1988). 
 
All cognitive domains, except BACS composite, were entered into stepwise multiple linear 
regressions in order to assess the relationship between cognitive performance, clinical 
symptoms and functioning at baseline in the CHR group. Multivariable logistic regression 
models were constructed to predict CHR participants’ functional outcome at 6-and 12-
months since the outcome variable was dichotomous (GFO was coded as 0 and PFO was 
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coded as 1). Potential clinical, functional and cognitive variables were initially computed 
individually in univariable logistic regression analyses. Next, two multivariable logistic 
regressions using stepwise backward selection (likelihood ratio) were employed because 
these analyses were primarily exploratory. Cognitive variables that reached a borderline 
significance (p < 0.10) in univariable analyses were entered in the first model. In the 
second model, cognitive variables included in the first model were entered alongside 
clinical and functional variables that reached a significance level of p < 0.10 in univariable 
analyses. Although the logistic regression analyses violated the widely advocated ten 
events per variable (EPV) rule, Vittinghoff and McCulloch (2007) have argued that an 
EPV of 10 as a minimal guideline criterion is too conservative, showing that severe 
problems mainly occur in models with 2-4 EPV. 
 
The overall variance explained by the models obtained through stepwise linear and logistic 
regressions was measured by the R2 statistic and Nagelkerke pseudo R2 statistic (R2N), 
respectively. Diagnostic accuracy of the logistic regression models was determined with 
area under the receiver operating characteristic (ROC) curves (AUC).
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3.0 Results 
 
3.1 Baseline. 
 
Baseline demographic, clinical and functional characteristics of CHR individuals, HCs and CHR-Ns are summarised in Table 4.  
 
Table 4 
Baseline Characteristics of CHR Individuals, HCs and CHR-Ns 
Characteristic CHRs 
(n = 129) 
HCs  
(n = 55) 
CHR-N 
(n = 46) 
df 
 
F/ X2/H p Post Hoc Contrasts * 
Age (years), M ± SD 21.64 ± 4.28 22.31 ± 3.38 23.00 ± 4.84 2, 102 F = 1.64 0.199  
Gender, N female (%) 97 (75) 37 (67) 29 (63) 2 X2 = 2.88 0.237  
Years of education, M ± SD 15.29 ± 3.17 16.38 ± 2.84 16.46 ± 3.48 2, 227 F = 3.57 < 0.05  
UK Citizen, N (%) 90 (70) 26 (47) 23 (50) 2 X2 = 10.78 < 0.01  
GAF, median (range) 58 (21-95) 88 (67-97) 70 (43-94) 2 H = 116.83 < 0.001 1 vs 2,3 & 2 vs 3 
CAARMS Positive Items, median (range)        
Unusual Thought Content 1 (0-5) 0 (0-1) 0 (0-5) 2 H = 47.97 < 0.001 1 vs 2,3 & 2 vs 3 
Non-Bizarre Ideas 3 (0-6) 0 (0-2) 0 (0-5) 2 H = 97.88 < 0.001 1 vs 2,3 
Perceptual Abnormalities 3 (0-6) 0 (0-3) 0 (0-4) 2 H = 101.36 < 0.001 1 vs 2,3 & 2 vs 3 
Disorganised Speech 1 (0-4) 0 (0-1) 0 (0-3) 2 H = 55.88 < 0.001 1 vs 2,3 & 2 vs 3 
Total Positive Severity 28 (0-72) 0 (0-12) 5 (0-24) 2 H = 143.43 < 0.001 1 vs 2,3 & 2 vs 3 
CHR Criteria Subgroup, N (%)        
UHR 41 (32) 0 (0) 0 (0)     
BS 32 (25) 0 (0) 0 (0)     
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UHR/BS 54 (42) 0 (0) 0 (0)     
GF: Social, median (range) 8 (5-10) 9 (8-10) 8 (6-9) 2 H = 73.10 < 0.001 1 vs 2,3 & 2 vs 3 
GF: Role, median (range) 8 (4-9) 9 (5-9) 8 (5-9) 2 H = 57.16 < 0.001 1 vs 2,3 & 2 vs 3 
Medication, N (%)    10 X2 = 41.96 < 0.001  
Anti-psychotic 2 (2) 0 (0) 1 (2)     
Mood stabiliser  1 (1) 0 (0) 0 (0)     
Anti-depressant  29 (22) 0 (0) 10 (22)     
Other 15 (12) 1 (2) 6 (13)     
Multiple 17 (13) 0 (0) 2 (4)     
Diagnosis, N (%)    2 X2 = 125.89 < 0.001  
Anxiety disorders 92 (71) 0 (0) 21 (46)     
Mood disorders 82 (64) 0 (0) 13 (28)     
Eating disorders 11 (9) 0 (0) 1 (2)     
Suicide Risk 67 (52) 1 (2) 10 (22)     
Alcohol Dependence/Abuse 40 (31) 2 (4) 10 (22)     
Substance Dependence/Abuse 19 (15) 0 (0) 2 (4)     
Note. Abbreviations: CHR, clinical high-risk; HC, healthy control; CHR-N, clinical high-risk-negative. * 1 = CHRs, 2= HCs, 3 = CHR-Ns. 
 
CHR individuals had significantly poorer global, social and role functioning as well as significantly higher intensity scores on all CAARMS 
positive items compared to HCs and CHR-Ns. Except for the non-bizarre ideas CAARMS positive item, CHR-Ns were also significantly 
impaired on these measures compared to HCs. Significant group differences were found for years of education, citizenship, medication use and 
MINI diagnoses. That said, no significant post hoc differences were observed for years of education.  
 
Table 5 displays the baseline neurocognitive and social cognitive performance for CHR individuals, CHR-Ns and HCs. Due to incorrect task 
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performance, one CHR participant was removed from the CNB working memory analyses while two CHR-N participants and two CHRs with 
PFO were removed from the CNB attention analyses.  
 
Table 5 
Baseline Cognitive Performance of CHR Individuals, HCs and CHR-Ns 
Domain CHR 
(n = 129) 
HCs 
(n = 55) 
CHR-N  
(n = 46) 
df F p Cohen’s d Post Hoc Contrasts * 
M SD M SD M SD      
BACS 
Verbal Memory -0.14 1.20 0 1 0.14 1.04 2, 227 1.39 0.252 0.17  
Motor Speed -0.68 1.15 0 1 -0.32 0.92 2, 227 8.52 < 0.001 0.58 1 vs 2 
Attention & Processing Speed -0.41 1.08 0 1 0.12 1.14 2, 227 5.50 < 0.01 0.36 1 vs 3 
Verbal Fluency -0.15 0.97 0 1 -0.23 0.86 2, 227 0.72 0.454 0.14  
Executive Function -0.07 1.24 0 1 0.01 1.15 2, 227 0.08 0.921 0  
Working Memory -0.02 1.44 0 1 0.26 1.13 2, 114 0.97 0.381 0  
BACS Composite Score -0.54 1.62 0 1 -0.01 1.28 2, 115 4.81 < 0.05 0.36 1 vs 2 
CNB 
Emotion Recognition Accuracy -0.12 1.09 0 1 -0.10 0.92 2, 227 0.26 0.773 0.11  
Emotion Recognition RT 0.62 1.62 0 1 0.18 1.34 2, 113 5.09 < 0.01 0.39 1 vs 2 
Attention Accuracy -0.48 1.87 0 1 0.09 1.14 2, 120 3.39 < 0.05 0.26  
Attention RT -0.10 0.87 0 1 -0.28 0.98 2, 223 1.17 0.312 0.11  
Working Memory Accuracy -0.31 1.40 0 1 -0.16 1.24 2, 110 1.40 0.251 0.22  
Working Memory RT -0.03 0.82 0 1 -0.12 0.99 2, 226 0.20 0.822 0  
Note. RT (response time). Effect sizes between CHR and HC groups, measured by Cohen’s d, are classified as small (0.2), medium (0.5) and large (0.8). * 1 = CHRs, 
2 = HCs, 3 = CHR-Ns 
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Significant group differences were demonstrated for motor speed (F(2, 227) = 8.52, p < 
0.001), attention and processing speed (F(2, 227) = 5.50, p < 0.01), BACS composite 
score (F(2, 115) = 4.81, p < 0.05), emotion recognition RT (F(2, 113) = 5.09, p < 0.01) 
and attention accuracy (F(2, 120) = 3.39, p < 0.05). Specifically, CHR individuals had 
slower motor speed, poorer BACS composite scores and increased emotion recognition 
RTs compared to HCs and reduced attention and processing speed compared to CHR-Ns. 
No significant post hoc differences were observed for attention accuracy although the 
difference between CHRs and both CHR-Ns (p = 0.052) and HCs (p = 0.071) approached 
significance. 
 
Effect sizes (Cohen’s d) between CHR and HC groups for each cognitive domain are 
illustrated in Figure 2. 
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Figure 2. Effect sizes for BACS and CNB domains, as measured by Cohen’s d, between CHRs and HCs at baseline: classified as small (0.2), 
medium (0.5) and large (0.8). Error bars indicate standard errors of the mean. Positive values indicate worse performance while negative values 
indicate better performance compared to HCs. 
 
When comparing CHR individuals to HCs, a medium effect size was found for motor speed (d = 0.58).  
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All BACS and CNB cognitive domains, except BACS composite, were entered into 
stepwise multiple linear regressions in order to assess the relationship between cognitive 
performance, clinical symptoms and functioning at baseline in the CHR group (Table 6). 
 
Table 6 
Linear Regression for the Effects of Cognitive Performance on Clinical Symptoms and 
Functioning at Baseline in CHR participants  
Variable B SE β R2 F p 
GAF 
Emotion Recognition RT -2.10 0.90 -0.17 0.03 5.47 < 0.05 
CAARMS-Positive Severity 
Emotion Recognition RT 3.23 0.95 0.25    
    0.08 7.48 < 0.01 
Attention RT -3.05 1.48 -0.15    
Social Functioning  
Emotion Recognition RT -0.20 0.05 -0.27    
Emotion Recognition Accuracy 0.21 0.07 0.20 0.14 9.88 < 0.001 
Verbal Memory 0.14 0.07 0.15    
Role Functioning 
Emotion Recognition RT -0.17 0.06 -0.21 
 
  
    0.09 8.55 < 0.001 
Attention & Processing Speed 0.16 0.08 0.15    
RT (response time).  
 
Emotion recognition RT significantly predicted global functioning, accounting for 3% of 
the variance. Emotion recognition RT and attention RT combined to significantly predict 
CAARMS positive severity scores, accounting for 8% of the variance. Emotion 
recognition RT also combined with emotion recognition accuracy and verbal memory to 
significantly predict social functioning, explaining 14% of the variance while emotion 
recognition RT together with attention and processing speed significantly predicted role 
functioning, explaining 9% of the variance.  
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3.2 6-month follow-up. 
 
Baseline demographic, clinical and functional characteristics of CHR individuals with GFO and PFO at 6-month follow-up, HCs and CHR-Ns 
are summarised in Table 7.  
 
Table 7 
Baseline Characteristics of CHR Individuals Grouped by Functional Outcome at 6 Months, HCs and CHR-Ns 
Characteristic CHRs 
 
HCs  
(n = 55) 
CHR-N 
(n = 40) 
df 
 
F/ X2/H p Post Hoc Contrasts * 
GFO 
(n = 34) 
PFO 
(n = 52) 
    Overall GFO vs 
PFO 
 
Age (years), M ± SD 21.21 ± 3.17 21.42 ± 4.26 22.31 ± 3.39 23.00 ± 4.79 3, 92  F = 1.71 0.171 0.993  
Gender, N female (%) 28 (82) 37 (71) 37 (67) 28 (70) 3 X2 = 2.50 0.475 0.237  
Years of education, M ± SD 15.32 ± 2.68 15.31 ± 3.50 16.38 ± 2.84 16.35 ± 3.51 3, 177 F = 1.67 0.176 1.000  
UK Citizen, N (%) 20 (59) 36 (69) 26 (47) 18 (45) 3 X2 = 7.40 0.060 0.361  
GAF, median (range) 68 (21-91) 57 (43-80) 88 (67-97) 69.50 (43-94) 3 H = 109.55 < 0.001 < 0.01  3 vs 1, 2, 4 & 2 vs 1, 4 
CAARMS Positive Items, median (range)          
Unusual Thought Content 0 (0-5) 2 (0-5) 0 (0-1) 0 (0-5) 3 H = 41.31 < 0.001 0.744 3 vs 1, 2, 4 & 2, 4 
Non-Bizarre Ideas 3 (0-5) 3 (0-6) 0 (0-2) 0 (0-5) 3 H = 80.70 < 0.001 1.000 3, 4 vs 1, 2  
Perceptual Abnormalities 3 (0-5) 3 (0-5) 0 (0-3) 0 (0-4) 3 H = 88.04 < 0.001 1.000 3, 4 vs 1, 2 
Disorganised Speech 1 (0-4) 0 (0-4) 0 (0-1) 0 (0-3) 3 H = 39.05 < 0.001 1.000 3 vs 1, 2, 4 
Total Positive Severity 23.50 (4-72) 28.50 (0-58) 0 (0-12) 5 (0-24) 3 H = 122.13 < 0.001 1.000 3 vs 1, 2, 4 & 4 vs 1, 2 
CHR Criteria Subgroup, N (%)     9 X2 = 186.78 < 0.001 0.254  
UHR 13 (38) 16 (31) 0 (0) 0 (0)      
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BS 10 (29) 10 (19) 0 (0) 0 (0)      
UHR/BS 11 (32) 26 (50) 0 (0) 0 (0)      
GF: Social, median (range) 8 (6-10) 7 (5-9) 9 (8-10) 8 (6-9) 3 H = 60.49 < 0.001 < 0.01 2 vs 1, 3, 4 & 3 vs 1, 4  
GF: Role, median (range) 8 (6-9) 7 (4-9) 9 (5-9) 8 (5-9) 3 H = 76.90 < 0.001 < 0.001 2 vs 1, 3, 4 
Medication, N (%)     15 X2 = 54.88 < 0.001 0.283  
Anti-psychotic 1(3) 0 (0) 0 (0) 1 (3)      
Mood stabiliser  1 (3) 0 (0) 0 (0) 0 (0)      
Anti-depressant  4 (12) 12 (23) 0 (0) 10 (25)      
Other 5 (15) 6 (12) 1 (2) 6 (15)      
Multiple 4 (12) 11 (21) 0 (0) 2 (5)      
Diagnosis, N (%)     3 X2 = 99.80 < 0.001 0.146  
Anxiety disorders 19 (56) 43 (83) 0 (0) 20 (50)      
Mood disorders 15 (44) 34 (65) 0 (0) 13 (33)      
Eating disorders 5 (15) 4 (8) 0 (0) 1 (3)      
Suicide Risk 10 (29) 34 (65) 1 (2) 10 (25)      
Alcohol Dependence/Abuse 11 (32) 17 (33) 2 (4) 10 (25)      
Substance Dependence/Abuse 3 (9) 11 (21) 0 (0) 2 (5)      
Note. Abbreviations: CHR, clinical high-risk; HC, healthy control; CHR-N, clinical high-risk-negative. * 1 = CHRs with GFO, 2 = CHRs with PFO, 3 = HCs, 4 = CHR-Ns. 
 
Of the 86 CHR participants, 52 (60%) had a PFO whereas 34 (40%) had a GFO at 6-month follow-up. Groups did not differ significantly on age, 
gender, years of education or citizenship.  
 
CHR individuals with PFO exhibited the following significant differences: poorer global functioning compared to those with GFO and CHR-Ns; 
higher intensity scores on unusual though content than CHR-Ns; and reduced role and social functioning compared to all three groups. CHR 
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individuals with GFO and PFO had significantly higher intensity scores on two CAARMS-
positive items – non-bizarre ideas and perceptual abnormalities – compared to HCs and 
CHR-Ns as well as significantly higher CAARMS total positive severity than CHR-Ns. 
HCs had significantly better global functioning as well as lower scores for three 
CAARMS-positive items - unusual thought content, disorganised speech and total positive 
severity - than all other groups. They also displayed significantly better social functioning 
compared to CHR individuals with GFO and CHR-Ns.  
 
Significant differences between groups were also found for CHR criteria subgroup met, 
medication use and MINI diagnoses. However, these significant differences disappeared 
when solely comparing CHR individuals with GFO and PFO.  
 
Changes in functioning over the 6- and 12-month follow-up period were explored using 
three measures – GAF, GF: Role and GF: Social – for CHR individuals with GFO and 
PFO at 6-months (Table 8). Only CHR participants who had been retested twice since 
baseline - first at 6 months and then again at 12 months - were included in the analysis. 
 
Table 8 
Changes in Functioning for CHR Groups with GFO and PFO at 6 Months 
 Baseline 6 Months 12 Months Baseline vs 6 
months 
Baseline vs 12 
Months 
Median Range Median Range Median Range Z p Z p 
GFO Group (N = 26) 
GAF 68 40-91 70.50 67-94 78 47-88 -1.77 0.077 -1.94 0.053 
GF: Role 8 6-9 8 7-9 8 5-9 -0.29 0.771 -0.49 0.623 
GF: Social 8 6-10 8 6-9 8 6-9 -0.39 0.695 -0.74 0.463 
PFO Group (N = 37) 
GAF 58 43-80 58 21-64 58 21-80 -1.52 0.128 -0.34 0.735 
GF: Role 7 4-9 8 2-9 8 4-9 -1.05 0.294 -1.12 0.263 
GF: Social 7 6-9 7 5-9 8 5-10 -1.39 0.165 -0.10 0.919 
 
CHR individuals with GFO and PFO at 6 months showed relatively stable global, role and 
social functioning between baseline and both 6- and 12-months. Notably, in the GFO 
group, global functioning improvements approached significance between both baseline 
and 6 months (Z = -1.77, p = 0.077) and baseline and 12 months (Z = -1.94, p = 0.053). 
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Table 9 displays the baseline neurocognitive and social cognitive performance for CHR 
individuals with GFO and PFO at 6-month follow-up, CHR-Ns and HCs. Due to incorrect 
task performance, one CHR participant was removed from the CNB working memory 
analyses while two CHR-N participants and two CHRs with PFO were removed from the 
CNB attention analyses.  
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Table 9 
Baseline Cognitive Performance of CHR Individuals Grouped by Functional Outcome at 6 Months, HCs and CHR-Ns 
Domain CHR HCs 
(n = 55) 
CHR-N  
(n = 40) 
df F p Post Hoc 
Contrasts * 
GFO vs PFO 
GFO (n= 34) PFO (n = 52)        
M SD M SD M SD M SD     p Cohen’s d 
BACS 
Verbal Memory 0.21 1.12 -0.40 1.12 0 1 0.20 1.08 3, 177 3.33 < 0.05  0.064 0.54 
Motor Speed -0.53 1.10 -1.05 1.20 0 1 -0.43 0.93 3, 177 9.02 < 0.001 2 vs 3, 4 0.153 0.44 
Attention & Processing Speed 0.13 1.13 -0.85 1.01 0 1 0 1.23 3, 177 8.47 < 0.001 2 vs 1, 3, 4 < 0.001 0.92 
Verbal Fluency -0.05 0.91 -0.30 0.91 0 1 -0.22 0.87 3, 177 1.14 0.336  0.772 0.28 
Executive Function 0.30 0.95 -0.17 1.20 0 1 -0.06 1.20 3, 177 1.32 0.271  0.275 0.42 
Working Memory 0.45 1.42 -0.51 1.41 0 1 0.19 1.15 3, 177 4.79 < 0.01 2 vs 1, 4 < 0.01 0.68 
BACS Composite Score 0.17 1.51 -1.20 1.43 0 1 -0.12 1.34 3, 177 10.89 < 0.001 2 vs 1, 3, 4 < 0.001 0.92 
CNB 
Emotion Recognition Accuracy 0.21 0.90 -0.27 1.09 0 1 -0.15 0.94 3, 177 1.74 0.161  0.175 0.46 
Emotion Recognition RT 0.44 1.56 0.79 1.85 0 1 0.23 1.40 3, 87 2.69 0.051 2 vs 3 0.781 0.20 
Attention Accuracy -0.23 1.48 -0.51 1.36 0 1 0.12 1.11 3, 173 2.34 0.075  0.885 0.20 
Attention RT -0.13 0.76 0.01 1.00 0 1 -0.31 1.04 3, 173 1.00 0.393  0.986 0.16 
Working Memory Accuracy -0.09 1.47 -0.48 1.49 0 1 -0.29 1.29 3, 176 1.35 0.260  0.689 0.26 
Working Memory RT -0.11 0.69 0 0.81 0 1 -0.15 1.04 3, 176 0.31 0.818  0.994 0.14 
Note. RT (response time). Effect sizes between CHR GFO and PFO groups, measured by Cohen’s d, are classified as small (0.2), medium (0.5) and large (0.8). 
* 1 = CHRs with GFO, 2 = CHRs with PFO, 3 = HCs, 4 = CHR-Ns 
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Significant group differences were demonstrated for verbal memory (F(3, 177) = 3.33, p 
> 0.05), motor speed (F(3, 177) = 9.02, p < 0.001), attention and processing speed (F(3, 
177) = 8.47, p < 0.001), working memory (F(3, 177) = 4.79, p < 0.01) and BACS 
composite score (F(3, 177) = 10.89, p < 0.001), while a trend was observed for emotion 
recognition RT (F(3, 87) = 2.69, p = 0.051).  
 
Specifically, CHR individuals with PFO showed the following significant differences: 
reduced attention and processing speed and BACS composite score compared to the other 
three groups; slower motor speed compared to HCs and CHR-Ns; increased emotion 
recognition RTs compared to HCs; and poorer working memory when compared to CHR 
individuals with GFO and CHR-Ns. No significant post hoc differences were observed for 
verbal memory although the difference between CHR individuals with PFO and both 
CHR-Ns (p = 0.052) and CHR individuals with GFO (p = 0.064) approached significance.  
 
Effect sizes (Cohen’s d) between CHR GFO and PFO groups for each cognitive domain 
are illustrated in Figure 3. 
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Figure 3. Effect sizes for BACS and CNB domains, as measured by Cohen’s d, between CHRs with GFO and PFO at 6 months: classified as 
small (0.2), medium (0.5) and large (0.8). Error bars indicate standard errors of the mean. Positive values indicate worse performance while 
negative values indicate better performance compared to CHRs with GFO. 
 
When comparing CHR individuals with PFO and GFO, large effect sizes were found for attention and processing speed (d = 0.92) and BACS 
composite score (d = 0.92) while medium to large effect sizes were found for working memory (d = 0.68) and verbal memory (d = 0.54).  
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Clinical, functional and cognitive variables were then tested individually with univariable 
logistic regressions to examine possible baseline predictors of CHR functional outcome at 
6 months (Table 10). To avoid redundancy, CAARMS total positive severity was included 
instead of single CAARMS positive items and BACS composite was omitted. 
 
Table 10 
Univariable Logistic Regression Analyses for Prediction of 6-Month Functional Outcome  
Variable B SE Wald p OR (95% CI) 
Clinical 
CAARMS Total Positive Severity 0.016 0.014 1.337 0.248 1.016 (0.989-1.044) 
Functional 
GAF -0.097 0.026 14.005 < 0.001 0.908 (0.863-0.955) 
GF: Role -1.409 0.348 16.417 < 0.001 0.244 (0.124-0.483) 
GF: Social -0.980 0.286 11.736 < 0.01 0.375 (0.214-0.657) 
BACS 
Verbal Memory -0.508 0.216 5.526 < 0.05 0.602 (0.394-0.919) 
Motor Speed -0.403 0.206 3.821 0.051 0.669 (0.447-1.001) 
Attention & Processing Speed -0.935 0.270 11.994 < 0.01 0.392 (0.231-0.666) 
Verbal Fluency -0.313 0.250 1.562 0.211 0.731 (0.448-1.194) 
Executive Function -0.407 0.220 3.424 0.064 0.666 (0.433-1.024) 
Working Memory -0.528 0.185 8.136 < 0.01 0.590 (0.410-0.848) 
CNB 
Emotion Recognition Accuracy -0.518 0.257 4.079 < 0.05 0.595 (0.360-0.985) 
Emotion Recognition RT 0.123 0.135 0.829 0.363 1.131 (0.868-1.474) 
Attention Accuracy -0.149 0.166 0.812 0.367 0.861 (0.622-1.092) 
Attention RT 0.177 0.250 0.500 0.480 1.193 (0.731-1.948) 
Working Memory Accuracy -0.207 0.178 1.352 0.245 0.813 (0.574-1.152) 
Working Memory RT 0.198 0.298 0.440 0.507 1.219 (0.679-2.186) 
Note. RT (response time). Abbreviations: SE, standard error; OR, odds ratio; CI, confidence interval  
 
Functional variables that reached a significance level of p < 0.10 included global 
functioning (OR = 0.908, 95% CI = 0.863-0.955, p < 0.001); role functioning (OR = 
0.244, 95% CI = 0.124-0.483, p < 0.001); and social functioning (OR = 0.375, 95% CI = 
0.214-0.657, p < 0.01). 
 
Cognitive variables that reached a significance level of p < 0.10 included verbal memory 
(OR = 0.602, 95% CI = 0.394-0.919, p < 0.05); motor speed (OR = 0.669, 95% CI = 
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0.447-1.001, p = 0.051); attention and processing speed (OR = 0.392, 95% CI = 0.231-
0.666, p < 0.01); executive function (OR = 0.666, 95% CI = 0.433-1.024, p = 0.064); 
working memory (OR = 0.590, 95% CI = 0.410-0.848, p < 0.01); and emotion recognition 
accuracy (OR = 0.595, 95% CI = 0.360-0.985. p < 0.05). 
 
Two multivariable logistic regressions using stepwise backward selection (likelihood ratio) 
were used to determine whether these variables could successfully predict 6-month 
functional outcome for CHR individuals (Table 11). Cognitive variables that reached a 
significance level of p < 0.10 in univariable analyses were entered in the first model. In the 
second model, cognitive variables included in the first model were entered alongside 
clinical and functional variables that reached a significance level of p < 0.10 in univariable 
analyses. No sources of multicollinearity were identified among potential predictor 
variables (tolerance: 0.634 to 0.789, VIF: 1.268 to 1.578). 
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Table 11 
Multivariable Logistic Regression Models for Prediction of 6-Month Functional Outcome 
Variable B SE Wald p OR (95% CI) AUC (SE) [95% CI] R2N Sensitivity Specificity 
Model 1 – Cognition 
Emotion Recognition Accuracy -0.589 0.329 3.119 0.074 0.555 (0.291-1.058)     
Attention & Processing Speed -0.769 0.274 7.885 < 0.01 0.463 (0.271-0.793) 0.816 (0.048) [0.722-0.910] 0.363 82.7 58.8 
Working Memory -0.541 0.207 6.817 < 0.01 0.582 (0.388-0.874)     
Model 2 – Combined 
Attention & Processing Speed -1.289 0.442 8.490 < 0.01 0.276 (0.116-0.656)     
Working Memory -0.462 0.229 4.092 < 0.05 0.630 (0.402-0.986)     
GAF -0.103 0.034 9.388 < 0.01 0.902 (0.845-0.964) 0.911 (0.032) [0.849-0.973] 0.623 0.904 0.765 
GF: Role -1.178 0.431 7.454 < 0.01 0.308 (0.132-0.717)     
Note. AUC values are classified as acceptable (0.7), good (0.8) and excellent (0.9). Abbreviations: SE, standard error; OR, odds ratio; CI, confidence interval; AUC, area 
under the curve; R2N, Nagelkerke pseudo R2 statistic 
 
Model 1 accounted for 36.3% of the variance in CHR participants’ 6-month functional outcome (R2N = 0.363). Baseline attention and processing 
speed (OR = 0.463, 95% CI = 0.271-0.793, p < 0.01) and working memory (OR = 0.582, 95% CI = 0.388-0.874, p < 0.01) were significant 
predictors of 6-month functional outcome for CHR individuals while emotion recognition accuracy (OR = 0.555, 95% CI = 0.291-1.058, p = 
0.074) did not contribute significantly to the model. 
 
Model 2 accounted for 62.3% of the variance in CHR participants’ 6-month functional outcome (R2N = 0.623). Baseline attention and processing 
(OR = 0.276, 95% CI = 0.116-0.656, p < 0.01); working memory (OR = 0.630, 95% CI = 0.402-0.986, p < 0.05); global functioning (OR =
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0.902, 95% CI = 0.845-0.964, p < 0.01); and role functioning (OR = 0.308, 95% CI = 
0.132-0.717, p < 0.01) were significant predictors of 6-month functional outcome for CHR 
individuals. 
 
The receiver-operating characteristic (ROC) curves for these models are shown below 
(Figure 4). 
 
 
Figure 4. Receiver-operating characteristic (ROC) curves for the multivariable logistic 
regression models predicting 6-month functional outcome 
 
The area under the curve for model 1 was 0.816 (95% CI = 0.722-0.910, p < 0.001), 
indicating a good discriminative ability, with a sensitivity of 82.7% and specificity of 
58.8%. The area under the curve for model 2 was 0.911 (95% CI = 0.849-0.973, p < 
0.001), indicating an excellent discriminative ability, with a sensitivity of 90.4% and 
specificity of 76.5%.  
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3.3 12-month follow-up. 
 
Baseline demographic, clinical and functional characteristics of CHR individuals with GFO and PFO at 12-month follow-up, HCs and CHR-Ns 
are summarised in Table 12.  
 
Table 12 
Baseline Characteristics of CHR Individuals Grouped by Functional Outcome at 12 months, HCs and CHR-Ns 
Characteristic CHRs 
 
HCs  
(n = 55) 
CHR-Ns 
(n = 40) 
df 
 
F/ X2/H p Post Hoc Contrasts * 
GFO 
(n = 34) 
PFO 
(n = 35) 
    Overall  GFO vs 
PFO 
 
Age (years), M ± SD 22.15 ± 3.74 21.97 ± 5.07 22.31 ± 3.39 23.00 ± 4.79 3, 79 F = 0.34 0.796 0.998  
Gender, N female (%) 26 (76) 27 (77) 37 (67) 28 (70) 3 X2 = 1.48 0.686 0.947  
Years of education, M ± SD 16.03 ± 3.34 15.54 ± 3.91 16.38 ± 2.84 16.35 ± 3.51 3, 160 F = 0.53 0.665 0.991  
UK Citizen, N (%) 20 (59) 25 (71) 26 (47) 18 (45) 3 X2 = 6.91 0.075 0.272  
GAF, median (range) 63.50 (40-91) 56 (40-80) 88 (67-97) 69.50 (43-94) 3 H = 94.57 < 0.001 0.122 3 vs 1, 2, 4 & 2 vs 4 
CAARMS Positive Items, median (range)          
Unusual Thought Content 0 (0-5) 2 (0-5) 0 (0-1) 0 (0-5) 3 H = 43.84 < 0.001 < 0.05 3 vs 1, 2, 4 & 2 vs 1, 4 
Non-Bizarre Ideas 3 (0-5) 3 (0-6) 0 (0-2) 0 (0-5) 3 H = 83.20 < 0.001 1.000 3, 4 vs 1, 2  
Perceptual Abnormalities 3 (0-5) 3 (0-6) 0 (0-3) 0 (0-4) 3 H = 87.50 < 0.001 1.000 3, 4 vs 1, 2 
Disorganised Speech 0 (0-4) 2 (0-4) 0 (0-1) 0 (0-3) 3 H = 46.15 < 0.001 0.435 3 vs 1, 2, 4 & 2 vs 4 
Total Positive Severity 21 (4-72) 37 (9-66) 0 (0-12) 5 (0-24) 3 H = 123.18 < 0.001 0.790 3 vs 1, 2, 4 & 4 vs 1, 2 
CHR Criteria Subgroup, N (%)     9 X2 = 188.97 < 0.001 < 0.01  
UHR 12 (35) 13 (37) 0 (0) 0 (0)      
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BS 12 (35) 2 (6) 0 (0) 0 (0)      
UHR/BS 10 (29) 20 (57) 0 (0) 0 (0)      
GF: Social, median (range) 8 (6-10) 7 (5-9) 9 (8-10) 8 (6-9) 3 H = 59.14 < 0.001 0.377 3 vs 1, 2, 4 & 2 vs 4 
GF: Role, median (range) 8 (6-9) 7 (4-9) 9 (5-9) 8 (5-9) 3 H = 38.01 < 0.001 0.081 3 vs 1, 2 & 2 vs 4 
Medication, N (%)     15 X2 = 59.24 < 0.001 0.661  
Anti-psychotic 0 (0) 0 (0) 0 (0) 1 (3)      
Mood stabiliser  1 (3) 0 (0) 0 (0) 0 (0)      
Anti-depressant  5 (15) 7 (20) 0 (0) 10 (25)      
Other 5 (15) 5 (14) 1 (2) 6 (15)      
Multiple 4 (12) 7 (20) 0 (0) 2 (5)      
Diagnosis, N (%)     3 X2 = 90.25 < 0.001 0.720  
Anxiety disorders 21 (62) 27 (77) 0 (0) 20 (50)      
Mood disorders 18 (53) 19 (56) 0 (0) 13 (33)      
Eating disorders 3 (9) 4 (12) 0 (0) 1 (3)      
Suicide Risk 13 (38) 20 (59) 1 (2) 10 (25)      
Alcohol Dependence/Abuse 8 (24) 10 (29) 2 (4) 10 (25)      
Substance Dependence/Abuse 4 (12) 3 (9) 0 (0) 2 (5)      
Note. Abbreviations: CHR, clinical high-risk; HC, healthy control; CHR-N, clinical high-risk-negative. * 1 = CHRs with GFO, 2 = CHRs with PFO, 3 = HCs, 4 = CHR-Ns. 
 
Of the 69 CHR participants, 35 (51%) had a PFO whereas 34 (49%) had a GFO at 12-months follow-up. Groups did not differ significantly on 
age, gender, years of education or citizenship.  
 
Intensity scores on unusual thought content were significantly poorer for CHR individuals with PFO, versus GFO. CHR individuals with PFO 
had significantly lower global, role and social functioning as well as higher intensity scores on unusual thought content and disorganised speech
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- compared to CHR-Ns. CHR individuals with GFO and PFO also displayed significantly 
poorer role functioning relative to HCs; significantly higher CAARMS total positive 
severity scores compared to CHR-Ns; and significantly higher intensity scores on two 
CAARMS-positive items – non-bizarre ideas and perceptual abnormalities – compared to 
both HCs and CHR-Ns. HCs had significantly better global and social functioning as well 
as lower intensity scores on three CAARMS positive items – unusual thought content, 
disorganised speech and total positive severity - than all other groups.  
 
Significant differences between groups were also found for CHR criteria subgroup met, 
medication use and MINI diagnoses. When solely comparing CHR individuals with GFO 
and PFO, these significant differences disappeared for medication use and MINI diagnoses 
but remained for CHR criteria subgroup met. Indeed, CHR individuals with PFO were 
more likely to meet UHR/BS criteria and less likely to meet BS criteria alone than CHR 
individuals with GFO. 
 
Changes in functioning over the 6- and 12-month follow-up period were explored using 
three measures – GAF, GF: Role and GF: Social – for CHR individuals with GFO and 
PFO at 12 months (Table 13). Only CHR participants who had been retested twice since 
baseline - first at 6 months and then again at 12 months - were included in the analysis. 
 
Table 13 
Changes in Functioning for CHR Groups with GFO and PFO at 12 Months 
 Baseline 6 Months 12 Months Baseline vs 6 
months 
Baseline vs 12 
Months 
Median Range Median Range Median Range Z p Z p 
GFO Group (N = 31) 
GAF 63 40-91 68 53-94 78 67-88 -2.00 < 0.05 -4.01 < 0.001 
GF: Role 8 6-9 8 7-9 8 6-9 -0.55 0.581 -0.17 0.868 
GF: Social 8 6-10 8 6-9 8 6-10 -0.17 0.864 -2.17 < 0.05 
PFO Group (N = 32) 
GAF 57 43-80 58 21-81 51 21-64 -1.54 0.124 -3.38 < 0.01 
GF: Role 7 4-9 8 2-9 8 4-9 -0.38 0.702 -0.77 0.439 
GF: Social 7.50 6-9 7 5-9 7 5-9 -1.81 0.070 -1.06 0.291 
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CHR individuals with GFO and PFO group displayed relatively stable role and social 
functioning between baseline and both 6- and 12-months. In the GFO group, global 
functioning improved between baseline and 6 months (Z = -2.00, p < 0.05) while global 
functioning (Z = -4.01, p = < 0.001) and social functioning (Z = -2.17, p = < 0.05) 
improved between baseline and 12 months. In the PFO group, global functioning worsened 
between baseline and 12 months (Z = -3.38, p = < 0.01), while declines in social 
functioning between baseline and 6 months approached significance (Z = -1.81, p = 0.070). 
 
Table 14 displays the baseline neurocognitive and social cognitive performance for CHR 
individuals with GFO and PFO at 12-month follow-up, CHR-Ns and HCs. Due to incorrect 
task performance, one CHR participant was removed from the CNB working memory 
analyses while two CHR-N participants and two CHRs with PFO were removed from the 
CNB attention analyses. 
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Table 14 
Baseline Cognitive Performance of CHR Individuals Grouped by Functional Outcome at 12 Months, HCs and CHR-Ns 
Domain CHR HCs 
(n = 55) 
CHR-N  
(n = 39) 
df F p Post Hoc 
Contrasts * 
GFO vs PFO 
GFO (n= 34) PFO (n = 35)        
M SD M SD M SD M SD     p Cohen’s d 
BACS 
Verbal Memory 0 1.21 -0.12 1.23 0 1 0.20 1.08 3, 160 0.53 0.661  0.999 0.09 
Motor Speed -0.79 1.07 -1.11 1.12 0 1 -0.43 0.93 3, 160 9.81 < 0.001 3 vs 1, 2 & 2 vs 4 0.717 0.30 
Attention & Processing Speed -0.18 1.27 -0.69 1.13 0 1 0 1.23 3, 160 3.11 < 0.05 2 vs 3 0.342 0.43 
Verbal Fluency -0.10 0.75 -0.29 0.99 0 1 -0.22 0.87 3, 160 0.85 0.469  0.949 0.22 
Executive Function 0.07 1.53 -0.18 0.97 0 1 -0.06 1.20 3, 160 0.24 0.870  0.965 0.18 
Working Memory -0.14 1.35 -0.10 1.65 0 1 0.19 1.15 3, 160 0.52 0.670  1.000 0 
BACS Composite Score -0.44 1.65 -0.92 1.72 0 1 -0.12 1.34 3, 76 3.15 < 0.05 2 vs 3 0.647 0.29 
CNB 
Emotion Recognition Accuracy 0.10 0.98 -0.10 0.95 0 1 -0.15 0.94 3, 160 0.47 0.705  0.955 0.20 
Emotion Recognition RT 0.41 1.41 1.04 1.87 0 1 0.23 1.40 3, 77 3.28 < 0.05 2 vs 3 0.395 0.39 
Attention Accuracy 0.07 1.16 -0.78 1.45 0 1 0.12 1.11 3, 156 4.49 < 0.01 2 vs 1, 3, 4 < 0.05 0.65 
Attention RT -0.08 0.80 -0.13 0.95 0 1 -0.31 1.04 3, 156 0.80 0.494  1.000 0.06 
Working Memory Accuracy -0.39 1.64 -0.56 1.61 0 1 -0.29 1.29 3, 159 1.32 0.269  0.997 0.11 
Working Memory RT -0.11 0.75 0.06 0.82 0 1 -0.15 1.04 3, 159 0.40 0.756  0.975 0.21 
Note. RT (response time). Effect sizes between CHR GFO and PFO groups, measured by Cohen’s d, are classified as small (0.2), medium (0.5) and large (0.8). * 1 = CHRs with 
GFO, 2 = CHRs with PFO, 3 = HCs, 4 = CHR-Ns 
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Significant differences were evident between groups for motor speed (F(3, 160) = 9.81, p 
< 0.001), attention and processing speed (F(3, 160) = 3.11, p < 0.05), BACS composite 
score (F(3, 76) = 3.15, p < 0.05) emotion recognition RT (F(3, 77) = 3.28, p < 0.05) and 
attention accuracy (F(3, 156) = 4.49, p < 0.01).  
 
CHR individuals with GFO and PFO had significantly slower motor speed compared to 
HCs. Those with PFO also showed the following significant differences: slower motor 
speed than CHR-Ns; slower attention and processing speed, poorer BACS composite score 
and increased emotion recognition RT compared to HCs; and reduced attention accuracy 
relative to the other three groups. 
 
Effect sizes (Cohen’s d) between CHR GFO and PFO groups for each cognitive domain 
are illustrated in Figure 5.
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Figure 5. Effect sizes for BACS and CNB domains, as measured by Cohen’s d, between CHRs with GFO and PFO at 12 months: classified as 
small (0.2), medium (0.5) and large (0.8). Error bars indicate standard errors of the mean. Positive values indicate worse performance while 
negative values indicate better performance compared to CHRs with GFO. 
 
When comparing CHR individuals with PFO and GFO, a medium to large effect size was found for attention accuracy (d = 0.65). 
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Clinical, functional and cognitive variables were then tested individually with univariable 
logistic regressions to examine possible baseline predictors of CHR functional outcome at 
12 months (Table 15). To avoid redundancy, CAARMS total positive severity was 
included instead of single CAARMS positive items and BACS composite was omitted. 
 
Table 15 
Univariable Logistic Regression Analyses for Prediction of 12-Month Functional Outcome  
Variable B SE Wald p OR (95% CI) 
Clinical 
CAARMS Total Positive Severity 0.043 0.017 6.506 < 0.05 1.044 (1.010-1.080) 
Functional 
GAF -0.076 0.026 8.489 < 0.01 0.927 (0.881-0.975) 
GF: Role 0.817 0.290 7.927 < 0.01 0.442 (0.250-0.780) 
GF: Social -0.611 0.276 4.897 < 0.05 0.543 (0.316-0.933) 
BACS 
Verbal Memory -0.079 0.201 0.156 0.693 0.924 (0.623-1.370) 
Motor Speed -0.276 0.228 1.468 0.226 0.759 (0.485-1.186) 
Attention & Processing Speed -0.368 0.218 2.850 0.091 0.692 (0.451-1.061) 
Verbal Fluency -0.255 0.283 0.810 0.368 0.775 (0.445-1.350) 
Executive Function -0.141 0.194 0.524 0.469 0.869 (0.594-1.271) 
Working Memory 0.017 0.161 0.012 0.914 1.018 (0.742-1.397) 
CNB 
Emotion Recognition Accuracy -0.219 0.260 0.705 0.401 0.804 (0.483-1.339) 
Emotion Recognition RT 0.244 0.160 2.316 0.128 1.276 (0.932-1.746) 
Attention Accuracy -0.531 0.224 5.622 < 0.05 0.588 (0.379-0.912) 
Attention RT -0.068 0.283 0.057 0.811 0.934 (0.536-1.628) 
Working Memory Accuracy -0.064 0.153 0.173 0.678 0.938 (0.695-1.266) 
Working Memory RT 0.277 0.318 0.762 0.383 1.319 (0.708-2.459) 
Note. RT (response time). Abbreviations: SE, standard error; OR, odds ratio; CI, confidence interval  
 
The clinical variable, CAARMS total positive severity, reached a significance level of p 
< 0.10 (OR = 1.044, 95% CI = 1.010-1.080, p < 0.05). 
 
Functional variables that reached a significance level of p < 0.10 included global 
functioning (OR = 0.927, 95% CI = 0.881-0.975, p < 0.01); role functioning (OR = 0.442, 
95% CI = 0.250-0.780, p < 0.01); and social functioning (OR = 0.543, 95% CI = 0.316-
0.933, p < 0.05). 
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Cognitive variables that reached a significance level of p < 0.10 attention and processing 
speed (OR = 0.692, 95% CI = 0.451-1.061, p = 0.091) and attention accuracy (OR = 0.588, 
95% CI = 0.379-0.912, p < 0.05).  
 
Two multivariable logistic regressions using stepwise backward selection (likelihood ratio) 
were used to determine whether they these variables could successfully predict 12-month 
functional outcome for CHR individuals (Table 16). Cognitive variables that reached a 
significance level of p < 0.10 in univariable analyses were entered in the first model. In the 
second model, cognitive variables included in the first model were entered alongside 
clinical and functional variables that reached a significance level of p < 0.10 in univariable 
analyses. No sources of multicollinearity were identified among potential predictor 
variables (tolerance: 0.637 to 0.957, VIF: 1.045 to 1.571). 
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Table 16 
Multivariable Logistic Regression Models for Prediction of 12-Month Functional Outcome 
Variable B SE Wald p OR (95% CI) AUC (SE) [95% CI] R2N Sensitivity Specificity 
Model 1 – Cognition 
Attention Accuracy -0.531 0.224 5.622 < 0.05 0.588 (0.379-0.912) 0.692 (0.066) [0.563-0.820] 0.131 82.4 51.5 
Model 2 – Combined 
Attention Accuracy -0.634 0.251 6.387 < 0.05 0.531 (0.325-0.867)     
CAARMS Total Positive Severity 0.036 0.021 2.982 0.084 1.036 (0.995-1.079) 0.818 (0.053) [0.713-0.923] 0.351 0.727 0.706 
GAF -0.062 0.031 4.150 < 0.05 0.940 (0.885-0.998)     
Note. AUC values are classified as acceptable (0.7), good (0.8) and excellent (0.9). Abbreviations: SE, standard error; OR, odds ratio; CI, confidence interval; AUC, area 
under the curve; R2N, Nagelkerke pseudo R2 statistic 
 
Model 1 accounted for 13.1% of the variance in CHR participants’ 12-month functional outcome (R2N = 0.131). Baseline attention accuracy (OR 
= 0.588, 95% CI = 0.379-0.912, p < 0.05) was a significant predictor of 12-month functional outcome for CHR individuals. 
 
Model 2 accounted for 35.1% of the variance in CHR participants’ 12-month functional outcome (R2N = 0.351). Baseline attention accuracy (OR 
= 0.531, 95% CI = 0.325-0.867, p < 0.05) and global functioning (OR = 0.940, 95% CI = 0.885-0.998, p < 0.05) were significant predictors of 
12-month functional outcome for CHR individuals while CAARMS total positive severity (OR = 1.036, 95% CI = 0.995-1.079, p = 0.084) did 
not contribute significantly to the model.  
 
The ROC curves for these models is shown below (Figure 6). 
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Figure 6. Receiver-operating characteristic (ROC) curve for the multivariable logistic 
regression model predicting 12-month functional outcome 
 
The area under the curve for model 1 was 0.692 (95% CI = 0.563-0.820, p < 0.01), 
indicating that discriminative ability was nearly acceptable, with a sensitivity of 82.4% and 
specificity of 51.5%. The area under the curve for model 2 was 0.818 (95% CI = 0.713-
0.923, p < 0.001), indicating a good discriminative ability, with a sensitivity of 72.7% and 
specificity of 70.6%.  
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4.0 Discussion 
 
The present study set out to assess the relationship between cognitive performance, 
clinical symptoms and functioning at baseline and baseline predictors of functional 
outcome at 6- and 12-month follow-up in a sample of CHR participants primarily 
recruited from the general population. 
 
The baseline analyses yielded two main findings. First, functional and cognitive 
variables discriminated between CHR individuals and HCs at baseline. Second, 
cognitive performance was related to clinical symptoms and functioning at baseline. 
Additionally, the 6- and 12-month follow-up analyses yielded four main findings. First, 
a substantial proportion of CHR individuals had PFO at 6- and 12- months follow-up 
(60% and 51%, respectively). Second, levels of functioning remained relatively stable 
for CHR participants over 6- and 12-months. Third, baseline clinical, functional and 
neurocognitive variables, but not social cognitive variables, discriminated between CHR 
individuals with GFO and PFO at 6- and/or 12-months. Fourth, a combination of 
cognitive and functional variables at baseline provided the best prediction of functional 
outcome at 6- and 12-months. 
 
4.1 Baseline comparison of functioning and cognition. 
 
CHR individuals had significantly poorer global, social and role functioning compared 
to HCs and CHR-Ns. Similar impairments in global functioning, as measured by the 
GAF, and social and role functioning, as measured by the GF: Social and GF: Role 
scales, have been described in help-seeking CHRs, relative to HCs (Allen et al., 2015; 
Carrión et al., 2011; Schlosser et al., 2012). In comparison to these studies, CHR 
individuals included in the present investigation displayed considerably better levels of 
global, social and role functioning, perhaps owing to the large proportion of participants 
recruited from the general population and attending university in the current sample. 
Since significant differences were also evident between CHRs and CHR-Ns, these 
functioning impairments may be exclusively associated with the at-risk state. 
 
In the current study, CHR individuals had slower motor speed, poorer BACS composite 
scores and increased emotion recognition RTs compared to HCs as well as reduced 
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attention and processing speed compared to CHR-Ns. The symbol-coding measure of 
attention and processing speed is, reportedly, the best discriminator of CHRs and 
schizophrenia participants from HCs (Dickinson et al., 2007; Fusar-Poli et al., 2012b). 
Kelleher et al. (2013) also reached this conclusion in a CHR sample recruited from the 
general population. Although CHR participants in the present investigation displayed a 
similar processing speed deficit, with an associated effect size of d = 0.36, this result did 
not reach significance. Furthermore, the lack of a significant difference in processing 
speed when CHR samples are compared to non-CHR psychiatric controls in prior 
studies raises questions as to the specificity of this deficit, and others, to the at-risk state 
(Lin et al., 2013). However, in the current study, CHR-individuals did display 
significant impairments in attention and processing speed, relative to CHR-Ns, implying 
that this deficit may be specific to the at-risk state, rather than resulting from 
psychopathological characteristics common to all mental health disorders. 
 
On the other hand, motor speed deficits in heterogeneous CHR samples are reported less 
frequently with some studies reporting slowed motor speed (Dean & Mittal, 2015; 
Lencz et al., 2006; Gschwandtner et al., 2006) and others finding no differences (Dean 
et al., 2017; Giuliano et al., 2012). Interestingly, when comparing CHR individuals with 
HCs, the largest effect size in this study was obtained for motor speed (d = 0.58). 
Previous investigations have reported remarkably smaller motor speed effect sizes 
(Carrion et al., 2011, 2013; Lencz et al., 2006). However, motor system abnormalities in 
CHR participants are relatively understudied and only recently garnering attention, in 
contrast to other cognitive domains such as processing speed. Emotion recognition 
impairments have also been described in CHR samples compared to HCs (Kohler et al., 
2014, van Donkersgoed et al., 2015). However, these studies have primarily focused on 
tests of emotion recognition accuracy rather than emotion recognition RT. One of the 
few studies investigating emotion recognition RT found no significant differences 
between CHRs and HCs (Glenthøj et al., 2018), in contrast to results from the current 
study. Of note, deficits previously detected in verbal memory, verbal fluency, working 
memory and executive function in CHR individuals, relative to HCs, were not replicated 
in the current sample (Frommann et al., 2011; Fusar-Poli et al., 2012b). This is 
potentially a consequence of the recruitment strategy. By primarily targeting individuals 
from the general population, the current study permitted the investigation of cognitive 
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deficits earlier than is possible in clinically presenting, help-seeking samples, perhaps 
before the majority of cognitive deficits emerge.  
 
4.2 Cognitive predictors of clinical symptoms and functioning at baseline. 
 
In agreement with several prior studies, cognitive performance was significantly related 
to clinical symptoms and functioning at baseline (Carrión et al., 2011; Glenthøj et al., 
2016; Niendam et al., 2006). Interestingly, emotion recognition RT, either alone or in 
combination with other cognitive variables, predicted global, social and role 
functioning. Notably, emotion recognition accuracy also predicted social functioning. 
These findings concur with Glenthøj et al. (2016) who reported that the emotion 
recognition of anger and surprise was associated with social skill performance while the 
emotion recognition of disgust was associated with role functioning. In contrast, Cotter 
et al. (2017) did not identify an association between facial emotion recognition and 
functioning. This is likely a consequence of their extremely small sample size (n = 30) 
and, therefore, lack of power to detect an association.  
 
Verbal memory also combined with emotion recognition RT and emotion recognition 
accuracy to predict social functioning. Niendam et al. (2006) similarly demonstrated 
that deficits in verbal learning and memory were predictive of social functioning at 
baseline, irrespective of negative or positive symptom severity. On the other hand, 
attention and processing speed combined with emotion recognition RT to predict role 
functioning. Partially in line with these findings, Carrión et al. (2011) demonstrated that 
processing speed could predict 10% and 7% of the variance for social and role 
functioning, respectively. Notably, attention RT and emotion recognition RT emerged 
as predictors of CAARMS-positive severity scores. This novel finding suggests that 
attention RT and emotion recognition RT could potentially aid in the prediction of 
psychosis transition.  
 
It is important to highlight that, although cognitive variables were important for 
predicting both clinical symptoms and functioning, the amount of variance accounted 
for was relatively low. It is plausible to suggest that the inclusion of additional 
variables, such as negative symptoms, would increase the total amount of explained 
variance. For example, Glenthøj et al. (2016) found that emotion recognition RT in 
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combination with negative symptoms best predicted role functioning, accounting for 
35.7% of the variance. 
 
4.3 Outcome at 6- and 12-month follow-up. 
 
Consistent with previous findings in help-seeking samples (Addington et al., 2011; 
Carrión et al., 2013; de Wit et al., 2014), initial CHR categorisation was associated with 
persistent functional impairment. Nevertheless, fewer CHR participants presented with 
PFO at 12 months than 6 months, in line with previous findings of functional 
improvement over time in nonconverters (Addington et al., 2011). At the 6-month 
follow-up, 60% of the CHR sample had PFO whilst, at the 12-month follow-up, 51% 
had PFO. Several studies have found similar rates of PFO, from the higher rate of 64% 
in a 3-5 year study by Carrión et al. (2013) to the lower rates of 46% and 44% in studies 
spanning 6 years (Brandizzi et al., 2015) and 2 years (Schlosser et al., 2012), 
respectively. In contrast, even lower rates have been reported by Velthorst et al. (2013) 
after 3-6 years follow-up (36%) and by Salokangas et al. (2014) after 18-months follow-
up (37%).  
 
Moreover, of the 86 CHR individuals included in the 6-month follow-up analyses, five 
(6%) transitioned to psychosis while three (4%) of the 69 CHR individuals included in 
the 12-month follow-up analyses transitioned. Therefore, classification of CHR 
individuals into the PFO group was not entirely dependent on psychosis conversion, 
suggesting that functional outcome represents a more clinically relevant outcome than 
transition to psychosis.  
 
4.4 Changes in functioning over time. 
 
Across the study period, functioning levels remained largely stable for CHR participants 
with the following exceptions at 12-month follow-up: (1) global functioning scores 
increased between baseline and both 6- and 12-months for those in the GFO group; (2) 
social functioning improved between baseline and 12 months for those in the GFO 
group; and (3) global functioning scores worsened between baseline and 12 months for 
those in the PFO group. Carrión et al. (2013) found modest improvements in 
functioning for CHR individuals with good role and social outcomes while those with 
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poor role and social outcomes displayed impairments in functioning that were stable 
over time. Moreover, previous studies utilising heterogeneous CHR samples have 
shown that functioning is stable over time (Cornblatt et al., 2012), whereas others have 
found improvements, particularly in the year following CHR status identification 
(Addington et al., 2011). Recently, Addington et al. (2018) divided CHR nonconverters 
into three groups based on 2-year symptom ratings – remission, symptomatic and 
prodromal progression. Although the groups did not differ at baseline on either role or 
social functioning nor at 24 months on role functioning, significant improvements in 
social functioning were evident in the remission group at 24 months. Overall, current 
results closely concur with the aforementioned studies given that the majority of 
functioning parameters improved or remained stable over time. In order to characterise 
the functioning trajectory for CHR individuals with PFO, further research is required as 
existing findings are scarce and partially contradictory. 
 
4.5 Baseline clinical characteristics and functional outcome. 
 
Generally, CAARMS positive items measured at baseline did not discriminate between 
CHR individuals with PFO and GFO at 6- and 12-months, in accordance with past 
investigations (Brandizzi et al., 2015; Koutsouleris et al., 2018). In fact, more severe 
APS at baseline have been associated with psychosis conversion, rather than role or 
social functioning over an average follow-up of 3 years (Carrión et al., 2016a). 
Therefore, although positive symptoms may be distressing and attract attention 
clinically, they do not strongly associate with functional outcome. That said, one 
exception existed whereby CHR individuals with PFO at 12 months displayed 
significantly poorer intensity scores on unusual thought content compared to CHR 
individuals with GFO. However, this is likely a consequence of the smaller sample size 
included at 12 months compared to 6 months.  
 
4.6 Baseline functioning and functional outcome. 
 
Global, social and role functioning at baseline significantly discriminated between CHR 
individuals with GFO and PFO at 6 months. Specifically, the PFO group showed 
significantly poorer global, social and role functioning at baseline compared with the 
GFO group. Therefore, early detection and intervention is particularly critical for CHR 
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individuals with PFO, especially given that social and role skills are consolidated during 
late adolescence and early adulthood. At 12 months, no such group differences were 
found, possibly attributable to the smaller number of CHR individuals with PFO studied 
at this time point.  
 
Supporting results from the present study, Carrión et al. (2013) found that CHR 
individuals with poor role outcome, versus good role outcome, at follow-up had poorer 
role functioning at baseline and individuals with poor social outcome, versus good 
social outcome, at follow-up had poorer social functioning at baseline. Meanwhile, 
Koutsouleris et al. (2018) reported that CHR participants with impaired functioning at 
follow-up, regardless of whether this impairment related to social or role outcome, 
evidenced reduced role and social functioning at baseline, relative to unimpaired CHRs. 
Since similar results were detected independent of the measure used to define outcome, 
GAF is purported to be an effective measure of social and role functioning in the current 
sample. Nevertheless, it should be noted that social and role functioning levels in the 
current study greatly exceeded those reported by Carrión et al. (2013) and Koutsouleris 
et al. (2018). This finding may be particularly characteristic of the current sample 
recruited primarily from the general population and predominantly consisting of 
university students. 
 
Poorer global functioning scores have not previously been noted in individuals with 
PFO, relative to GFO, contradicting results from the current investigation (Brandizzi et 
al., 2015; Carrión et al., 2013; Lin et al., 2011). However, this inconsistency is relatively 
minor given that global functioning displays a considerable trend towards significance 
in these studies with p values of 0.06 and 0.08-0.10 reported by Lin et al. (2011) and 
Carrión et al. (2013), respectively. Compared to the present study, the baseline global 
functioning scores reported by Carrión et al. (2013) are around 20 and 12 points lower 
for both the GFO and PFO group, respectively. The GFO group studied by Lin et al. 
(2011) also possessed lower baseline global functioning scores, specifically by 6-9 
points, while the PFO group had similar scores to those found in the current study, only 
differing by 1-2 points. Therefore, unlike those with GFO, help-seeking individuals 
with PFO appear relatively similar to individuals with PFO recruited primarily from the 
general population. 
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In the current study, individuals at CHR for psychosis, irrespective of functional 
outcome group at 6- and 12-months, had significantly impaired global, social and role 
functioning at baseline, compared to HCs, with one exception. That is, no significant 
differences in baseline role functioning were observed between individuals with GFO at 
6 months and HCs, implying that PFOs are predominantly driven by low levels of role 
functioning. Therefore, role functioning represents an important target for early 
interventions focusing on vocational and educational rehabilitation. Indeed, vocational 
rehabilitation appears to be effective in both individuals with chronic schizophrenia 
(Bio & Gattaz, 2011) and young people with FEP (Killackey et al., 2018).  
 
Interestingly, CHR individuals with PFO, but not those with GFO, had significantly 
poorer global, social and role functioning at 6- and 12-months compared to CHR-Ns. 
Therefore, these functioning deficits appear to be specific to the underlying aetiology of 
PFO in CHR individuals, rather than resulting from psychopathological characteristics 
common to all mental health disorders. Similarly, albeit in a heterogeneous sample of 
help-seeking individuals, Addington et al. (2011) found poorer social and role 
functioning in CHR nonconverters, relative to a nonpsychiatric comparison group. 
Heinze et al. (2018) also found substantially lower levels of role functioning in 
heterogeneous, help-seeking CHR individuals compared to a nonpsychiatric comparison 
group across four time points –baseline and follow-up at 3-, 6- and 12-months. 
However, no group differences were observed for social functioning. 
 
4.7 Baseline cognition and functional outcome. 
 
Attention and processing speed, working memory and BACS composite score 
discriminated between CHR individuals with GFO and PFO at 6 months while attention 
accuracy discriminated between CHR individuals with GFO and PFO at 12 months. 
Specifically, the PFO group showed significantly lower scores on these neurocognitive 
domains than the GFO group. Notably, the BACS and CNB both contain tasks 
measuring attention and working memory. However, at 6 months, only BACS attention 
and working memory tasks were significant whereas, at 12 months, only the CNB 
attention accuracy task was significant. This indicates that working memory and 
attention cannot easily be conceptualised as simple unitary processes. Also, of note, 
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more cognitive domains reached significance at 6 months than 12 months, perhaps 
owing to the smaller sample of CHR individuals with PFO tested at the latter time point.   
 
Studies investigating neurocognitive performance in participants with GFO and PFO are 
scarce. In agreement with the current study, Carrión et al. (2013) found that CHR 
participants with poor social outcome had significantly impaired processing speed at 
baseline compared to those with good social outcome; while participants with poor role 
outcome had significantly impaired sustained attention at baseline compared to those 
with good role outcome. While Lin et al. (2011) also detected reduced performance on a 
task measuring attention and processing speed – the Trails A - for individuals with PFO 
compared to GFO, two other tasks of attention and processing speed – the symbol-
coding and digit span – although exhibiting a trend towards significance, did not differ 
significantly between the groups. Additionally, the present finding of impaired working 
memory in CHRs with PFO, versus GFO, at 6 months, contrasts with findings by 
Carrión et al. (2013) although somewhat concurs with previous evidence of differences 
in brain functional connectivity between remitters and non-remitters during working 
memory task performance (Liu et al., 2018). 
 
When comparing CHR individuals with PFO and GFO at 6 months, the largest effects 
sizes were found for attention and processing speed (d = 0.92) and BACS composite 
score (d = 0.92) while attention accuracy (d = 0.65) yielded the largest effect size when 
comparing CHR outcome groups at 12 months. Similarly, Lin et al. (2011) found effect 
sizes ranging between 0.44 and 0.84 when comparing CHR outcome groups on three 
different tasks of attention and processing speed. However, compared to the current 
study, a considerably lower effect size was reported for the symbol-coding task (d = 
0.53). This disparity may be due to the help-seeking sample, outcome classification 
method and/or longer follow-up duration used by Lin et al. (2011). It is worth noting 
that substantially smaller effect sizes were produced for attention accuracy (d = 0.20) 
and attention and processing speed (d = 0.43) when comparing the CHR outcome 
groups at 6- and 12-months, respectively. With a larger sample of CHRs with PFO at 12 
months, it is plausible that greater effect sizes would be produced for both attention 
accuracy and attention and processing speed. 
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Deficits previously detected in verbal memory, verbal fluency, motor speed and 
executive function in participants with PFO, versus GFO, were not replicated in the 
current sample (Carrión et al., 2013; Lin et al., 2011). This inconsistent result is 
possibly attributable to the general population sampling method, sample size and/or 
follow-up duration in the current study. Furthermore, there were no significant 
differences between the CHR outcome groups on the emotion recognition measures of 
social cognition. This result corroborates with Cotter et al. (2017) who concluded that 
the ToM measure of social cognition might have stronger associations with functioning 
than emotion recognition, highlighting the need for future studies to include a broad 
range of social cognitive measures.  
 
Notably, CHR individuals with PFO at 6- and 12-months had significantly reduced 
motor speed, attention and processing speed and BACS composite score and increased 
emotion recognition RT at baseline compared to HCs. At 12 months, reductions in 
attention accuracy were also evident in those with PFO relative to HCs. Interestingly, no 
significant differences were identified between CHR individuals with GFO at 6 months 
and HCs while CHR individuals with GFO at 12 months were only impaired relative to 
HCs on motor speed. This finding implies that the PFO and GFO group comprise 
separate and distinct groups with differing cognitive profiles. Indeed, Carrión et al. 
(2013) showed that performance on eight neurocognitive domains, including motor 
speed, sustained attention and processing speed, was significantly compromised only in 
those with PFO compared to HCs.  
 
In this study, CHR participants with PFO, but not GFO, at 6 months had significantly 
poorer motor speed, attention and processing speed, working memory and BACS 
composite score at baseline than CHR-Ns, suggesting that these deficits are unique to 
the 6-month poor outcome group. At 12 months, such group differences were only 
evident in baseline motor speed and attention accuracy. Notably, there were no 
significant differences in emotion recognition RT between CHR individuals in the PFO 
group at 6- and 12-months and CHR-Ns. Therefore, this impairment may not be specific 
to CHR individuals with PFO and, instead, may be associated with general 
psychopathology and distress which are common in CHR samples.  
 
4.8 Prediction of functional outcome.  
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In the current CHR sample, PFO at 6 months was significantly predicted by 
impairments in attention and processing speed, working memory, global functioning 
and role functioning at baseline whereas reduced attention accuracy and poor global 
functioning at baseline significantly predicted PFO at 12 months. 
 
Functioning has also been identified as a key predictor of CHR participants’ functional 
outcome in previous studies (Brandizzi et al., 2015; Koutsouleris et al., 2018). Brandizzi 
et al. (2015) found that baseline global functioning predicted functional outcome at 6-
years follow-up whilst Koutsouleris et al. (2018) reported that poor social functioning in 
the past year and poor social and role functioning over the lifetime, as measured by the 
GF: Social and GF: Role scales, were the most useful features for a model predicting 
social functioning. Although CAARMS total scores also predicted functional outcome 
in the former study, the positive symptoms total subscale alone did not, in line with the 
current results. Notably, in the latter study, the authors found less pronounced results for 
models predicting role functioning, implying that structural neuroimaging and 
functional data alone could not effectively determine role functioning outcome. 
 
Concurring with the present investigation, attention and processing speed and working 
memory at baseline have previously been found to predict functioning in CHR samples. 
Specifically, the symbol-coding measure of attention and processing speed has been 
found to predict functioning at 12 months, even after accounting for baseline symptoms 
(Meyer et al., 2014; Sawada et al., 2017). This has also been shown cross-sectionally 
(Carrión et al., 2011; Meyer et al., 2014) with Carrión et al. (2011) demonstrating that 
processing speed could predict 10% and 7% of the variance for social and role 
functioning at baseline, respectively. Additionally, Goghari et al. (2014) showed that 
spatial working memory measures were predictive of global functioning. In contrast to 
the final prediction models in the current study, verbal learning and memory, typically 
measured with the CVLT, has also been shown to predict functioning cross-sectionally 
and at 12 months (Meyer et al., 2014; Niendam et al., 2006). This inconsistency may 
relate to the verbal memory measure applied. For example, Sumiyoshi et al. (2017) 
noted that, while the CVLT (comprising four semantic categories) can discriminate 
between individuals with bipolar disorder and HCs, the BACS List Learning measure 
cannot. They suggest that individuals with bipolar disorder only have difficulty recalling 
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words if word lists are semantically organised which, it is reasonable to assume, may 
also be the case for individuals at CHR for psychosis.  
 
Only two previous studies (Carrión et al., 2013; Lin et al., 2011) have utilised binary 
logistic regression models to identify clinical, functional and neurocognitive predictors 
of functional outcome in individuals at CHR for psychosis. Partially in line with the 
current study, Carrión et al. (2013) found that poor social outcome was predicted by 
reduced processing speed, poor social functioning and total disorganised symptoms 
while poor role outcome was predicted by impaired verbal memory, poor role 
functioning and motor disturbances. Lin et al. (2011), on the other hand, deemed that 
neurocognitive and clinical variables most effectively predicted PFO. Specifically, PFO 
was predicted by impaired verbal learning and memory, verbal fluency and attention 
and processing speed, mostly in combination with higher negative symptoms. 
Impairments in verbal memory, verbal fluency and motor speed may have lacked 
predictive value in the current prediction models due to differences in the specific 
measures applied across studies. Meanwhile, the use of different recruitment strategies 
between Lin et al. (2011) and the present investigation potentially explains why 
functioning significantly predicted PFO only in the latter investigation.  
 
The clinical variables that significantly enhanced prediction of functional outcome in 
the aforementioned studies (Carrión et al., 2013; Lin et al., 2011) were not under 
investigation in the current study. Only positive symptoms were assessed and, in 
agreement with Lin et al. (2011), these did not significantly predict PFO. It is plausible 
to suggest that, in order to enhance prediction models, future studies should include a 
broader repertoire of clinical measurements. Indeed, the odds of poor social outcome are 
nearly 5 times greater in participants with a SOPS total disorganisation subscale score 
more than 4 at baseline (Carrión et al., 2013). 
 
In the present study, higher levels of accuracy, sensitivity, specificity and explained 
variance were achieved by integrating neurocognitive variables with functional 
variables. Moreover, the 6-month predictive model performed considerably better than 
both social and role outcome models in Carrión et al. (2013) while the 12-month 
predictive model performed slightly better than the role outcome model and slightly 
worse than the social outcome model. The exceptional performance of the 6-month 
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predictive model is possibly attributable to the number of functional variables included 
in the final model. Indeed, two functional variables – global functioning and role 
functioning - were included, in contrast to the models in Carrión et al. (2013) which 
both incorporated only one (either social functioning or role functioning). This further 
explains why the 12-month predictive model, featuring one functional variable (global 
functioning), is more similar to both Carrión et al. (2013) models in terms of accuracy, 
sensitivity, specificity and explained variance. 
 
The utility of combining neurocognitive measures with clinical and/or functional 
variables is further supported by psychosis conversion predictive models. In a risk 
calculator algorithm for psychosis conversion, T. D. Cannon et al. (2016) found that 
verbal learning and memory scores and speed of processing scores added modest, yet 
significant, independent predictive power above the following significant clinical and 
functional measures: unusual thought content, suspiciousness and social functioning. 
This individualised risk calculator has been further validated in an independent external 
dataset (Carrión et al., 2016a). That said, two previous studies concluded that 
neurocognitive data did not improve predictive power for psychosis conversion beyond 
multivariate clinical prediction models (Seidman et al., 2010; Ziermans et al., 2014). 
Overall, however, it is plausible to suggest that the accuracy of models predicting PFO 
and/or psychosis conversion will be strengthened by the addition of neurocognitive 
variables.  
 
4.9 Clinical and research implications. 
 
The online screening process utilised in this study provided a novel method of 
identifying young people with serious mental health problems, highlighting the 
usefulness of e-mental health applications for early diagnosis and potentially, early 
intervention. Indeed, such applications provide convenient access with regards to time 
and location; allow anonymity to counteract stigma; increase cost-effectiveness; and 
reduce the demand on clinicians. As evidenced in the present study, this approach is 
especially useful for investigating prodromal syndromes in the general population. 
Future studies should consider utilising general population samples in order to increase 
the generalisability of findings and to further explore clinical, functional and cognitive 
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characteristics in the very early stages of the prodrome; earlier than is possible in 
clinically presenting, help-seeking cases. 
 
Additionally, the current findings suggest that cognitive impairments negatively impact 
on multiple domains of real-world functioning. Deficits in attention and processing 
speed, working memory, attention accuracy and verbal memory, in particular, may 
hamper efforts to select and maintain conversational topics and/or focus on school- or 
course-work, household tasks and job responsibilities. Meanwhile, deficits in emotion 
recognition may result in socially inappropriate responses or ideas of persecution which 
are detrimental in both social and occupational settings. Early interventions targeting 
cognition, such as cognitive remediation, could potentially alleviate cognitive deficits 
and consequently improve functional outcome in clinical and research settings. A recent 
systematic review of six studies (Glenthøj, Hjorthøj, Kristensen, Davidson, & 
Nordentoft, 2017) provided preliminary evidence that cognitive remediation in the CHR 
population could improve cognition in the domains of verbal memory, attention and 
processing speed and functional outcome in the domains of social functioning and social 
adjustment. Future research, utilising a more rigorous methodological approach, is 
required to investigate the effectiveness of cognitive remediation alone and in 
conjunction with other interventions (e.g., vocational and educational rehabilitation). 
 
Continued refinement of functional outcome prediction models, with the aim of 
improving levels of accuracy, sensitivity, specificity and explained variance, is 
essential. This may be achieved by combining current models with neuroimaging, 
genetic, neurophysiological and neurochemical data. For example, there is recent 
evidence that functional outcome is predicted by neuregulin 1 (NRG1) gene expression 
(Jagannath et al., 2018) as well as thalamic glutamate levels and prefrontal-striatal 
activation (Allen et al., 2015). Furthermore, Koutsouleris et al. (2018) stated that, in 
uncertain cases, the addition of neuroimaging machine learning to clinical machine 
learning provides a 1.9-fold prognostic gain for CHR individuals.  
 
Although research, to date, has largely focused on the questionable outcome of 
“transition”, the current results suggest that outcomes other than transition should 
become the mainstream target for intervention. As well as finding support for the notion 
of declining transition rates, the present study found that nonconverters, traditionally 
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viewed as “false positives”, demonstrated impairments in cognition and social and role 
functioning that would likely benefit from treatment. Specifically, functional outcome 
appears to represent a more clinically relevant outcome. CHR individuals with GFO 
may represent a subgroup of false positive cases, suggesting that some refinement of the 
current CHR criteria is warranted. Certainly, subjecting these individuals to intense 
interventions may produce unintended consequences such as anxiety, stigma, 
discrimination and unnecessary treatment. Individuals with PFO, on the other hand, 
should be offered similar levels of support to those who convert to psychosis in order to 
help them cope with persistent cognitive as well as social and educational/occupational 
difficulties. 
 
4.10 Limitations. 
 
With regard to the gender composition of the current sample, a disproportionate number 
were female. Although the reason for this is not completely clear, it could reflect a 
greater willingness of female participants to engage in research studies and perhaps 
increased psychological knowledge and acceptance of mental health issues. If the latter 
is correct, different strategies must be employed to engage male participants in early 
intervention.  
 
In terms of the measurement procedure, functional outcome was based on the GAF 
scale – a measure which has been criticised for confounding symptoms and functioning, 
possibly leading to low scores even when social and role functioning are relatively 
spared. However, the GAF is frequently used to measure functioning and, consequently, 
offers a good and reliable possibility for comparisons with other studies. Separate 
functional measures that are not conflated with symptom severity, such as the GF: 
Social and GF: Role scales might increase construct validity. Additionally, negative 
symptoms, typically presenting many years before positive symptoms, were not 
thoroughly assessed in the current study although they reportedly play a prominent role 
in the impaired functioning of individuals at CHR for psychosis (Glenthøj et al., 2016; 
Salokangas et al., 2014; Schlosser et al., 2012). Indeed, Carrión et al. (2016b) found that 
longer negative symptom duration predicted poor social functioning. In contrast, neither 
positive symptom duration nor severity predicted role or social functioning. 
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Transition rates in the current study are relatively low given that several recent studies 
have reported rates of 13-20% (T. D. Cannon et al., 2016; Fusar-Poli et al., 2016; 
Seidman et al., 2016). Morrison et al. (2012) also noted that the prevalence of transition 
was lower than expected (8%). However, UHR status was defined on the basis of two 
baseline CAARMS assessments over 2-4 weeks to avoid under-reporting which led to 
the exclusion of 29 individuals who met CHR criteria at the first baseline visit. The 
inclusion of these 29 would have produced an overall transition rate of 18%, in line with 
the aforementioned studies. The low transition rate in the current study is likely 
reflective of the incomplete follow-up data collection at this time as well as the 
sampling method, whereby the majority of CHR participants were recruited from the 
general population. It also prevented further analysis of the characteristics of those who 
transitioned. 
 
4.11 Conclusions. 
 
The current study provides important new insights with regard to early detection and 
intervention in individuals at CHR for psychosis primarily recruited from the general 
population. Given that such a large proportion of CHR individuals presented with PFO 
at 6- and 12-months follow-up, the at-risk state appears to represent an appropriate 
intervention target, regardless of eventual conversion to psychosis. At baseline, 
neurocognitive and social cognitive performance were associated with clinical 
symptoms and functioning. Furthermore, CHR individuals with PFO, versus GFO, at 6- 
and 12-months follow-up were lower functioning and more cognitively impaired at 
baseline. These findings highlight the importance of such factors for detecting false 
positives as well as the potential benefits of interventions incorporating vocational and 
educational rehabilitation and cognitive remediation. Informed by the current findings, 
it is recommended that clinical early detection teams extend their services into the 
community in order to improve access to specialised interventions. Although replication 
in larger samples, over longer follow-up periods, is required to determine 
generalisability, it is clearly essential that clinicians and researchers alike focus on a 
broader outcome of interest in individuals at CHR for psychosis and not only on 
preventing transition to psychosis.  
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